Barney Scott Graham, MD, PhD - Publications

Publications in Peer-Reviewed Scientific Journals

  1. Cook B, O'Sullivan FX, Leung J, Morse P, Graham B, Chapman AL. Transformation of human embryo cells with the use of cell-free extracts of a human rhabdomyosarcoma cell line (HUS-2). Journal of the National Cancer Institute 1978; 60:979-983.
  2. Graham B, Fremon F. Continuous psychomotor seizures presenting as a long-standing mental illness. Southern Medical Journal 1982; 74:505-506.
  3. Graham BS, Reiss TF, Gregory DW. Pericarditis associated with Hemophilus influenzae type B pneumonia and bacteremia in two adults. Chest 1983; 84:48-50.
  4. Graham BS, Snell JD. Herpes simplex virus infection of the adult lower respiratory tract. Medicine 1983; 62:384-393.
  5. Graham BS, Hinson MV, Bennett SR, Gregory DW, Schaffner W. Acid-fast bacilli on buffy coat smears in the acquired immunodeficiency syndrome: A lesson from Hansen's bacillus. Southern Medical Journal 1984; 77:246-248.
  6. Graham B, Wong SW. Cancer cellulitis. Southern Medical Journal 1984; 77:277-278.
  7. Rabin PL, Graham BS. Counterfeit calculi. Southern Medical Journal 1984; 77:304-307.
  8. Graham BS, Tucker WS. Opportunistic infections in endogenous Cushing's syndrome. Annals of Internal Medicine 1984; 101:334-338.
  9. Graham BS, Gregory DW. Pseudomonas aeruginosa causing osteomyelitis after puncture wounds of the foot. Southern Medical Journal 1984; 77:1228-1230.
  10. Wheeler AP, Graham BS. Pseudogout presenting with low synovial fluid glucose: Identification of crystals by Gram stain. American Journal of Medical Sciences 1985; 289:68-69.
  11. Maples MD, Adkins RB, Graham BS, Dao AH, Scott HW. Pseudotumor of the lung. American Surgeon 1985; 51:84-88.
  12. George AL, Hays JT, Graham BS. Blastomycosis presenting as monoarticular arthritis: The role of synovial fluid cytology. Arthritis and Rheumatism 1985; 28:516-521.
  13. Fischmann GE, Graham BS. Ludwig's angina: Initial manifestation of oral malignancy. Journal of Oral Surgery 1985; 43:795-796.
  14. Graham BS, Lichtenstein MJ, Hinson JM, Theil GB. Non-exertional heatstroke: Physiologic management and cooling times in 14 patients. Archives of Internal Medicine 1986; 146:87-90.
  15. Adkins RB, Maples MD, Graham BS, Witt TT, Davies J. Dysphagia associated with an aortic arch anomaly in adults. American Surgeon 1986; 52:238-245.
  16. Graham BS, Johnson AC, Sawyers JL. Clostridial infection of a renal cell carcinoma. Journal of Urology 1986; 135:354-355.
  17. Decker MD, Graham BS, Hunter EB, Liebowitz SM. Endocarditis and infections of intravascular devices due to Eikenella corrodens. American Journal of Medical Sciences 1986; 29:209-212.
  18. Kopelman HA, Graham BS, Forman MB. Myocardial abscess with complete heart block complicating anaerobic infective endocarditis. British Heart Journal 1986; 56:101-104.
  19. Murphy BR, Graham BS, Prince GA, Walsh EE, Chanock RM, Karzon DT, Wright PF. The serum and nasal wash IgG and IgA antibody response of infants and children to the respiratory syncytial virus F and G glycoproteins following primary infection. Journal of Clinical Microbiology 1986; 23:1009-1014.
  20. Wagner DK, Graham BS, Wright PF, Walsh EE, Kim HW, Reimer CB, Nelson DL, Chanock RM, Murphy BR. The serum IgG subclass responses to respiratory syncytial virus F and G glycoproteins following primary infections. Journal of Clinical Microbiology 1986; 24:304-306.
  21. Murphy BR, Alling DW, Snyder MH, Walsh EE, Prince GA, Chanock RM, Hemming VG, Rodriguez WJ, Kim HW, Graham BS, Wright PF. Effect of age and preexisting antibody on serum antibody response of infants and children of the F and G glycoproteins during respiratory syncytial virus infection. Journal of Clinical Microbiology 1986; 24:894-898.
  22. Hendry RM, Burns JC, Walsh EE, Graham BS, Wright PF, Hemming VG, Rodriguez WJ, Kim HW, Prince GA, McIntosh K, Murphy BR. Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. Journal of Infectious Diseases 1988; 157:640-647.
  23. Graham BS, Perkins MD, Wright PF, Karzon DT. Primary respiratory syncytial virus infection in mice. Journal of Medical Virology. 1988; 26:153-162.
  24. Cooper JF, Lichtenstein MJ, Graham BS, Schaffner W. Mycobacterium chelonei: A cause of nodular skin lesions with proclivity for renal transplant patients. American Journal of Medicine 1989; 86:173-177.
  25. Wheeler AP, Graham BS. The spectrum of atypical mycobacterial infections. Southern Medical Journal 1989; 82(10):1250-1258.
  26. Graham BS, Wetherall NT. Growth of human cells in BALB/c mice. Cancer Research 1990; 50:5943-5946.
  27. Graham BS, Rowland JM, Modliszewski A, Montefiori DC. Anti-fusion activity in serum from HIV-1 infected persons. Journal of Clinical Microbiology 1990; 28:2608-2611.
  28. Dolin R, Graham BS, Greenberg SB, Tackett CO, Belshe RB, Midthun K, Clements ML, Gorse GJ, Horgan BW, Atmar RL, Karzon DT, Bonnez W, Fernie BF, Montefiori DC, Stablein DM, Smith GE, Koff WC, and the NIAID AIDS Vaccine Clinical Trials Network: Safety and immunogenicity of an HIV-1 recombinant gp160 candidate vaccine in humans. Annals of Internal Medicine 1991; 114:119-127.
  29. Graham BS, Bunton LA, Wright PF, Karzon DT. Reinfection of mice with respiratory syncytial virus. Journal of Medical Virology 1991; 34:7-13.
  30. Graham BS, Bunton LA, Wright PF, Karzon DT. Respiratory syncytial virus in anti-µ treated mice. Journal of Virology 1991; 65:4936-4942.
  31. Graham BS, Bunton LA, Wright PF, Karzon DT. The role of T cell subsets in the pathogenesis of primary infection and reinfection with respiratory syncytial virus in mice. Journal of Clinical Investigation 1991; 88:1026-1033.
  32. Lindgren C, Jing L, Graham BS, Grogard J, Sundell H. Respiratory syncytial virus infection reinforces reflex apnea in young lambs. Pediatric Research 1992; 31:381-385.
  33. Lagerstrom CF, Mitchell HG, Graham BS, Hammon JH. Chronic fibrosing mediastinitis and superior vena caval obstruction from blastomycosis. The Annals of Thoracic Surgery 1992; 54:764-765.
  34. Graham BS, Belshe RB, Clements ML, Dolin R, Corey L, Wright PF, Gorse GJ, Midthun K, Keefer MC, Roberts NJ, Jr, Schwartz DH, Agosti JM, Fernie BF, Stablein DM, Montefiori DC, Lambert JS, Hu S-L, Esterlitz JR, Lawrence D, Koff WC, and the AIDS Vaccine Clinical Trials Network. Vaccination of vaccinia-naive adults with HIV-1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. Journal of Infectious Diseases 1992; 166:244-252.
  35. Ukwu H, Graham BS, Lambert JS, Wright PF. Perinatal transmission of HIV-1 infection and immunization strategies for prevention. Obstetrics and Gynecology 1992; 80:458-468.
  36. Ukwu HN, Graham BS, Latham RH. Acute pubic osteomyelitis in athletic men. Clinical Infectious Diseases 1992; 15:636-638.
  37. Montefiori DM, Graham BS, Kliks S, Wright PF. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. Journal of Clinical Immunology 1992; 12:429-439.
  38. Edwards KM, Decker MD, Graham BS, Mezzatesta J, Scott J, Hackell J. Immunization of adults with acellular pertussis vaccine. Journal of the American Medical Association 1993; 269:53-56.
  39. Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, Corey L, Stablein DM, Esterlitz JR, Hu S-L, Smith G, Fast P, Koff WC, and the AIDS Vaccine Clinical Trials Network. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. Journal of Infectious Diseases 1993; 167:533-537.
  40. Pincus SH, Messer KG, Schwartz DH, Lewis GK, Graham BS, Blattner WA, Fisher G. Comparative analysis of antibody response to human immunodeficiency virus envelope in infected laboratory workers and vaccinees. Journal of Clinical Investigation 1993; 91:1987-1996.
  41. Montefiori DC, Graham BS, Zhou JT, Zhou JY, Bucco R, Schwartz DH, Cavacini LA, Posner MR, and the NIH-NIAID AIDS Vaccine Clinical Trials Network. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. Journal of Clinical Investigation 1993; 92:840-847. Accompanying editorial: Schooley RT. Just (don’t) do it. JCI 1993; 92:535.
  42. Graham BS, Davis TH, Tang YW, Bunton LA, Gruber WC. Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with RSV-specific immune serum. Pediatric Research. 1993; 34:167-172.
  43. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. Journal of Immunology 1993; 151:2032-2040.
  44. Hesselton RM, Koup RA, Cromwell MA, Graham BS, Johns M, Sullivan JL. Human peripheral blood xenografts in the SCID mouse: Characterization of immunological reconstitution. Journal of Infectious Diseases 1993; 168:630-640.
  45. Belshe RB, Clements ML, Dolin R, Graham BS, McElrath MJ, Gorse GJ, Schwartz D, Keefer MC, Wright PF, Corey L, Bolognesi DP, Matthews TJ, Stablein DM, O'Brien FS, Eibl M, Dorner F, Koff W, and the NIAID AIDS Vaccine Clinical Trials Network. Safety and immunogenicity of a fully glycosylated recombinant gp160 HIV-1 vaccine in low risk volunteers. Journal of Infectious Diseases 1993; 168:1387-1395.
  46. Neuzil KM, Gruber WC, Chytil F, Stahlman MT, Graham BS. Serum vitamin A levels in respiratory syncytial virus infection. Journal of Pediatrics 1994; 124:433-436.
  47. Neuzil KH, Mitchell HG, Loyd J, Lagerstrom CF, Hammon JH, Graham BS. Blastomycosis causing mediastinal fibrosis: Distinction from histoplasmosis. Chest 1994; 106:1885-1887.
  48. Belshe RB, Clements ML, Keefer MC, Graham BS, Corey L, Sposto R, Stablein DM, Lawrence D, and the AIDS Vaccine Clinical Trials Network. Interpreting HIV serodiagnostic test results in the 1990's: Social risks of HIV vaccine studies in uninfected volunteers. Annals of Internal Medicine 1994; 121:584-589.
  49. Graham BS, Gorse GJ, Schwartz DH, Keefer MC, McElrath J, Matthews TJ, Wright PF, Belshe RB, Clements ML, Dolin R, Corey L, Bolognesi DP, Stablein DM, Esterlitz JR, Hu S-L, Smith G, and the AIDS Vaccine Clinical Trials Network. Determinants of antibody response after rgp160 boosting in vaccinia-naive volunteers primed with gp160 recombinant vaccinia. Journal of Infectious Diseases 1994; 170:782-786.
  50. Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright PF, Dolin R, Matthews TJ, Weinhold K, Bolognesi DP, Sposto R, Stablein DM, Twaddell T, Berman PW, Gregory T, Izu AE, Walker MC, Fast PE, and the NIAID AIDS Vaccine Clinical Trials Network. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. Journal of the American Medical Association 1994; 272:475-480.
  51. Montefiori DC, Graham BS, Zhou JY, Zhou JT, Ahearn JM, and the AIDS Vaccine Clinical Trials Network. Binding of HIV-1 to the C3b/C4b receptor, CR1 (CD35), and red blood cells in the presence of complement and envelope-specific antibodies. Journal of Infectious Diseases 1994; 170:429-432.
  52. Keefer MC, Graham BS, Belshe RB, Schwartz DH, Corey L, Bolognesi DP, Stablein DP, Montefiori DC, McElrath J, Clements ML, Gorse GJ, Wright PF, Matthews TJ, Smith GE, Lawrence D, Dolin R, and the NIAID AIDS Vaccine Clinical Trials Network. Studies of high doses of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in HIV-1 seronegative humans. AIDS Research and Human Retroviruses 1994; 10:1713-1723.
  53. Tang YW, Graham BS. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. Journal of Clinical Investigation 1994; 94:1953-1958.
  54. Gorse GJ, Schwartz DH, Graham BS, Matthews TJ, Stablein DM, Belshe RB, Eibl M, Fast PE, and the AIDS Vaccine Clinical Trials Network. Human immunodeficiency virus type 1 recombinant gp160 given in accelerated dose schedules. Clinical and Experimental Immunology 1994; 98:178-184.
  55. Scott MA, Graham BS, Verrall R, Dixon R, Schaffner W, Tham KT. Rhodococcus equi: An increasingly recognized opportunistic pathogen: Report of 12 cases and review of the literature. American Journal of Clinical Pathology 1995; 103:649-655.
  56. Graham BS, Tang YW, Gruber WC. Topical immunoprophylaxis of respiratory syncytial virus (RSV)-challenged mice with RSV-specific immune globulin. Journal of Infectious Diseases 1995; 171:1468-1474.
  57. Neuzil KM, Gruber WC, Chytil F, Stahlman MT, Graham BS. Safety of vitamin A therapy for infants with respiratory syncytial virus infection. Antimicrobial Agents and Chemotherapy 1995; 39:1191-1193.
  58. Tang YW, Graham BS. Interleukin 12 treatment during immunization elicits a Th1-like immune response in mice challenged with respiratory syncytial virus and improves vaccine immunogenicity. Journal of Infectious Diseases 1995; 172:734-738.
  59. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS, and the AIDS Vaccine Evaluation Group. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. Journal of Infectious Diseases 1996; 173:340-348.
  60. Neuzil KM, Tang YW, Graham BS. Protective role of tumor necrosis factor-alpha in respiratory syncytial virus infection in vitro and in vivo. American Journal of Medical Sciences 1996; 311:201-204.
  61. Lindgren C, Lin J, Graham BS, Gray ME, Parker RA, Sundell HW. Respiratory syncytial virus infection enhances the response to laryngeal chemostimulation and inhibits arousal from sleep in young lambs. Acta Pediatrica 1996; 85:789-797.
  62. Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh RH, Chernoff D, Dekker C, Dolin R, and the AIDS Vaccine Clinical Trials Network. Safety and immunogenicity of env2-3, a human immunodeficiency virus type-1 candidate vaccine in combination with a novel adjuvant, MTP-PE/MF59. AIDS Research and Human Retroviruses 1996; 12:683-693.
  63. Graham BS, Keefer MC, McElrath J, Gorse GJ, Schwartz DH, Belshe RB, Clements ML, Dolin R, Corey L, Wright PF, Sposto R, Stablein DM, Chernoff D, Dekker C, and the AIDS Vaccine Clinical Trials Network. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant envelope glycoprotein gp120. Annals of Internal Medicine 1996; 125:270-279.
  64. Tang YW, Neuzil KM, Fischer JE, Robinson FW, Parker RA, Graham BS. Determinants and kinetics of cytokine expression in lungs of immunized mice challenged with respiratory syncytial virus. Vaccine 1997; 15:597-602.
  65. Neuzil KM, Johnson JE, Tang YW, Prieels JP, Slaoui M, Graham BS. Adjuvants influence the quantitative and qualitative immune response to respiratory syncytial virus FG subunit immunization in BALB/c mice. Vaccine 1997; 15:525-532.
  66. Pincus SH, Messer KG, Cole R, Ireland R, VanCott TC, Pinter A, Schwartz DH, Graham BS, Gorse GJ. Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. Journal of Immunology 1997; 158:3511-3520.
  67. Tang YW, Graham BS. T cell source of type 1 cytokines determines illness pattern in respiratory syncytial virus-infected mice. Journal of Clinical Investigation 1997; 99:2183-2191.
  68. Keefer MC, Wolff M, Gorse GJ, Graham BS, McElrath MJ, Schwartz DH, Savarese B, Stablein DM, Belshe RB, Wright PF, Corey L, Clements ML, Dolin R, Fast PE. Safety profile of phase I and II preventive HIV-1 vaccination: Experience of the AIDS Vaccine Evaluation Group. AIDS Research and Human Retroviruses 1997; 13:1163-1177.
  69. Fischer JE, Johnson JE, Kuli-Zade R, Johnson TR, Aung S, Parker RA, Graham BS. Overexpression of IL-4 delays virus clearance in mice infected with RSV. Journal of Virology 1997; 71:8672-8677.
  70. Corey L, McElrath MJ, Weinhold K, Matthews TJ, Stablein DM, Graham BS, Keefer MC, Schwartz DH, Gorse GJ, and the AIDS Vaccine Evaluation Group. Cytotoxic T cell and neutralizing antibody responses to HIV-1 envelope with a combination vaccine regimen. Journal of Infectious Diseases 1998; 177:301-309.
  71. Graham BS, McElrath MJ, Connor RI, Schwartz DH, Gorse GJ, Keefer MC, Mulligan MJ, Matthews TJ, Wolinsky SM, Montefiori DC, Vermund SH, Lambert JS, Corey L, Belshe RB, Dolin R, Wright PF, Korber BT, Wolff MC, Fast PE, and the AIDS Vaccine Evaluation Group. Analysis of intercurrent HIV-1 infections in Phase I and II trials of candidate AIDS vaccines. Journal of Infectious Diseases 1998; 177:310-319.
  72. Connor RI, Korber BTM, Graham BS, Hahn BH, Ho DD, Walker BD, Neumans A, Vermund S, Mestecky J, Jackson S, Cao Y, Gao F, Kalams S, Kuntsman K, McDonald D, Fenamore E, McWilliams N, Morrison S, Trkola A, Moore JP, Wolinsky SM. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. Journal of Virology 1998; 72:1552-1576.
  73. Clements-Mann ML, Matthews TJ, Weinhold K, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Hsieh RH, Schwartz D, Mestecky J, Zolla-Pazner S, Mascola J, Siliciano R, Corey L, Wright PF, Belshe R, Dolin R, Jackson S, Xu S, Fast PF, Walker MC, Stablein D, Excler JL, Tartaglia J, Duliege AM, Sinangil F, Paoletti E, and the AIDS Vaccine Evaluation Group. HIV-1 immune responses induced by canarypox (ALVAC)-gp160 MN, SF-2 rgp120, or both vaccines in seronegative adults. Journal of Infectious Diseases 1998; 177:1230-1246.
  74. Johnson TR, Johnson JE, Roberts SR, Wertz GW, Parker RA, Graham BS. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. Journal of Virology 1998; 72:2871-2880.
  75. Byrd VM, Graham BS, Stock KJ, Fogo A. A 17-year-old with rash, fever, myalgias, and nephritis. American Journal of Kidney Diseases 1998; 32:848-852.
  76. Peebles RS, Jr., Sheller JR, Johnson JE, Mitchell DB, Graham BS. Respiratory syncytial virus infection prolongs methacholine-induced airway hyperresponsiveness in ovalbumin-sensitized mice. Journal of Medical Virology 1999; 57:186-192.
  77. Gicheru MM, Otsyula M, KewalRamaniVN, Miller CJ, Robins H, Haigwood N, Spearman PW, Graham BS, Montefiori DC. Neutralizing antibody responses in African Green Monkeys naturally infected with simian immunodeficiency virus (SIVagm). Journal of Medical Primatology 1999; 28:97-104.
  78. Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori DM, Gorse GJ, Graham BS, McElrath MJ, Clements-Mann ML, Mulligan M, Fast PL, Walker MC, Excler JL, Duliege AM, Tartaglia J, and the NIAID AIDS Vaccine Evaluation Group. A canarypox vaccine expressing multiple HIV-1 genes given alone or with rgp120 elicits broad and durable CD8+ CTL responses in seronegative volunteers. Journal of Infectious Diseases 1999; 180:290-298.
  79. Fisher RG, Johnson JE, Dillon SB, Parker RA, Graham BS. Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge. Journal of Infectious Diseases 1999; 180:708-713.
  80. Fischer JE, Johnson TR, Peebles RS, Graham BS. Vaccination with pertussis toxin alters the antibody response to simultaneous respiratory syncytial virus challenge. Journal of Infectious Diseases 1999; 180:714-71.
  81. Fisher RG, Crowe JE, Johnson TR, Tang YW, Graham BS. Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus. Journal of Infectious Diseases. 1999; 180:1324-1327.
  82. Pastey MK, Crowe JE, Jr., Graham BS. RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. Journal of Virology 1999; 73:7262-7270.
  83. Johnson TR, Graham BS. Secreted respiratory syncytial virus (RSV) G protein induces IL-5, IL-13, and eosinophilia by an IL-4-independent mechanism. Journal of Virology 1999; 73:8485-8495.
  84. Aung S, Tang YW, Graham BS. IL-4 inhibits induction of cytotoxic T lymphocyte activity in mice infected with recombinant vaccinia virus expressing respiratory syncytial virus M2 protein. Journal of Virology 1999; 73:8944-8949.
  85. Pastey MK, Gower TL, Spearman PW, Crowe JE, Jr., Graham BS. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nature Medicine 2000; 6:35-40.
  86. Aung S, Graham BS. Differential regulation of perforin- and FasL-mediated cytotoxicity by IL-4. Journal of Immunology 2000; 164:3487-3493.
  87. Graham BS, Johnson TR, Peebles RS. Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology 2000; 48:237-247.
  88. Peebles RS, Dworski R, Collins RD, Jarzecka AK, Mitchell DB, Graham BS, Sheller JR. Cyclooxygenase inhibition increases IL-5 and IL-13 production and airway hyperresponsiveness in allergic mice. American Journal of Respiratory and Critical Care Medicine 2000; 162:676-681.
  89. McElrath MJ, Corey L, Montefiori D, Wolff M, Schwartz D, Keefer M, Belshe R, Graham BS, Matthews T, Wright P, Gorse G, Dolin R, Berman P, Francis D, Duliége AM, Bolognesi D, Stablein D, Ketter N, Fast P. A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS Research and Human Retroviruses. 2000; 16:907-919.
  90. Peebles RS, Sheller JR, Collins RD, Jarzecka K, Mitchell DB, Graham BS. RSV-induced airway hyperresponsiveness in allergically-sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. Journal of Infectious Diseases 2000; 182:671-677.
  91. Fischer JE, Johnson JE, Johnson TR, Graham BS. Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infection. Journal of Infectious Diseases 2000; 182:1029-1038.
  92. Peebles RS, Sheller JR, Collins RD, Jarzecka AK, Mitchell DB, Parker RA, Graham BS. Respiratory syncytial virus infection decreases allergen-induced type 2 cytokine production while increasing airway hyperresponsiveness in mice. Journal of Medical Virology 2001; 63:178-188.
  93. Evans TG, McElrath MJ, Matthews TJ, Montefiori DC, Wolff M, Keefer MC, Kallas EG, Corey L, Gorse GJ, Belshe RB, Graham BS, Spearman PW, Schwartz D, Clements ML, Mulligan MJ, Goepfert P, Fast PE, Francis D, and the NIAID AIDS Vaccine Evaluation Group. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 2001; 19:2080-2091.
  94. Gower TL, Graham BS. Anti-viral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrobial Agents and Chemotherapy 2001; 45:1231-1237.
  95. AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 env, gag, and pro in combination with rgp120. Journal of Infectious Diseases 2001; 183:563-570.
  96. Gower TL, Peeples ME, Collins PL, Graham BS. RhoA is activated during respiratory syncytial virus infection. Virology 2001; 283:188-196. (Cover Photomicrograph)
  97. Johnson TR, Fischer JE, Graham BS. Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine. Journal of General Virology 2001; 82:2107-2116.
  98. Aung S, Rutigliano JA, Graham BS. Alternative mechanisms of respiratory syncytial virus clearance in perforin knockout mice lead to enhanced disease. Journal of Virology 2001; 75:9918-9924.
  99. Peebles RS, Hashimoto K, Collins RD, Jarzecka K, Furlong J, Mitchell DB, Sheller JR, Graham BS. Immune interaction between respiratory syncytial virus infection and allergen-sensitization critically depends on timing of challenges. Journal of Infectious Diseases 2001; 184:1374-1379.
  100. Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, Gorse GJ, Frey SE, Keefer MC, Evans TG, Dolin R, Schwartz DH, Harro C, Graham B, Spearman PW, Mulligan M, Goepfert P. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. Journal of Acquired Immune Deficiency Syndrome 2002; 29:254-261.
  101. Durbin J, Johnson TR, Durbin RK, Mertz S, Peebles RS, Jr., Graham BS. The role of interferon in RSV pathogenesis. Journal of Immunology 2002; 168:2944-2951.
  102. Peebles RS, Hashimoto K, Morrow JD, Dworski R, Collins RD, Jarzecka K, Mitchell DB, Graham BS, Sheller JR. Selective cyclooxygenase-1 and –2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice. American Journal of Respiratory and Critical Care Medicine 2002; 165:1154-1160. Accompanying editorial: Peters-Golden M. Open mind, open airways: Broadening the paradigm of prostaglandins and allergic airway inflammation. AJRCCM 2002; 165:1035-1036.
  103. Hashimoto K, Peebles RS, Sheller JR, Jarzecka K, Furlong J, Mitchell DB, Graham BS. A Rho kinase inhibitor, Y-27632, suppresses airway hyperresponsiveness induced by ovalbumin sensitization and RSV infection. Thorax 2002; 57:524-527.
  104. Johnson TR, Hong S, Van Kaer L, Altman JD, Koezuka Y, Graham BS. NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus. Journal of Virology 2002; 76:4294-4303.
  105. Wright PF, Gruber WC, Peters M, Reed G, Zhu YW, Robinson F, Coleman-Dockery S, Graham BS. Illness severity, virus shedding, and antibody responses in patients hospitalized with bronchiolitis caused by respiratory syncytial virus. Journal of Infectious Diseases 2002; 185:1011-1018.
  106. Lee CG, Homer RJ, Cohn L, Link H, Jung S, Craft JE, Graham BS, Johnson TR, Elias JA. Transgenic overexpression of IL-10 in the lung causes mucus metaplasia, tissue inflammation and airways remodeling via IL-13-dependent and -independent pathways. Journal of Biological Chemistry 2002; 277:35466-35474.
  107. McCurdy LH, Graham BS. The role of the plasma membrane lipid microdomain in respiratory syncytial virus filament formation. Journal of Virology 2003; 77:1747-1756.
  108. Johnson TR, Parker RA, Johnson JE, Graham BS. IL-13 is sufficient for respiratory syncytial virus (RSV) G glycoprotein-induced eosinophilia following RSV challenge. Journal of Immunology 2003; 170:2037-2045.
  109. Tang YW, Johnson JE, Browning PJ, Cruz-Gervis RA, Davis A, Graham BS, Brigham KL, Oates JA, Jr, Loyd JE, Stecenko AA. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. Journal of Clinical Microbiology 2003; 41:2633-2640. Commentary in Lancet Infectious Diseases 2003; 3:458.
  110. Budge P, Graham BS. Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on the formation of peptide dimers. Antimicrobial Agents and Chemotherapy 2003; 47:3470-3477.
  111. Rutigliano J, Hollinger T, Fischer JE, Johnson TR, Aung S, Johnson JE, Graham BS. Anti-LFA-1 treatment prevents respiratory syncytial virus-induced illness and delays virus clearance. Journal of Virology 2004; 78:3014-3023.
  112. McCurdy LH, Larkin BD, Martin JE, Graham BS. Modified vaccinia virus Ankara: Potential as an alternative smallpox vaccine. Clinical Infectious Diseases 2004; 38:1749-1753.
  113. Budge PJ, Li Y, Beeler JA, Graham BS. RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus, including disruption of viral attachment and dependence on RSV G. Journal of Virology 2004; 78:5015-5022.
  114. Lee D, Graham BS, Chiu YL, Gilbert P, McElrath MJ, Belshe R, Buchbinder S, Sheppard HW, Koblin B, Mayer K, Keefer M, Mulligan M, Celum C. Breakthrough infections during Phase I-II prime-boost HIV vaccine trials with canarypox vectors (ALVACTM) and recombinant gp120 or gp160. Journal of Infectious Diseases 2004; 190:903-907.
  115. Johnson TR, Teng MN, Collins PL, Graham BS. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV (FI-RSV). Journal of Virology 2004; 78:6024-6032.
  116. Johnson TR, Varga SM, Braciale TJ, Graham BS. Vβ14+ T cells do not mediate the vaccine-enhanced disease induced by immunization with formalin-inactivated RSV (FI-RSV). Journal of Virology 2004; 78:8753-8760. (Recommended by Faculty of 1000).
  117. Hashimoto K, Graham BS, Ho SB, Adler KB, Collins RD, Olson SJ, Zhou W, Goleniewska K, O’Neal JF, Peebles RS Jr. Respiratory syncytial virus in allergic lung inflammation increases Muc5ac and gob-5. American Journal of Respiratory and Critical Care Medicine 2004; 170:306-312.
  118. Rutigliano JA, Graham BS. Prolonged production of tumor necrosis factor alpha exacerbates illness during respiratory syncytial virus infection. Journal of Immunology 2004; 173:3408-3417.
  119. McCurdy LH, Rutigliano JA, Johnson TR, Chen M, Graham BS. Modified vaccinia Ankara immunization protects against lethal challenge with recombinant vaccinia expressing murine IL-4. Journal of Virology 2004; 78:12471-12479. (Recommended by Faculty of 1000).
  120. Hashimoto K, Graham BS, Geraci MW, FitzGerald GA, Egan K, Zhou W, Goleniewska K, O’Neal JF, Morrow JD, Durbin RK, Wright PF, Collins RD, Suzutani T, Peebles RS Jr. Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness. Journal of Virology 2004; 78:10303-10309.
  121. Agwale SM, Tanimoto L, Womack C, Odarna L, Leung K, Duey D, Negedu-Momoh R, Audu I, Mohammed DB, Inyang U, Graham B, Ziermann R. Prevalence of HCV coinfection in HIV-infected individuals in Nigeria and characterization of HCV genotypes. Journal of Clinical Virology 2004; 31 Supplement 1:S3-S6.
  122. Hashimoto K, Sheller JR, Morrow JD, Collins RD, Goleniewska K, O’Neal J, Zhou W, Ji S, Mitchell DB, Graham BS, Peebles RS. Cyclooxygenase inhibition augments allergic inflammation through CD4-dependent, STAT6-independent mechanisms. Journal of Immunology 2005; 174:525-532.
  123. Gower TL, Pastey MK, Peeples ME, Collins PL, Hart TK, Guth A, Johnson TR, Graham BS. RhoA signaling is required for RSV-induced syncytia formation and filamentous virion morphology. Journal of Virology 2005; 79:5326-5336.
  124. Hashimoto K, Durbin J, Zhou W, Collins RD, Ho SB, Sheller JR, Goleniewska K, O’Neal JF, Olson SJ, Mitchell D, Graham BS, Peebles RS. Respiratory syncytial virus infection in the absence of STAT1 results in airway dysfunction, induction of airway mucus, and augmented IL-17 production. Journal of Allergy and Clinical Immunology 2005; 116:550-557.
  125. Rutigliano RA, Rock MT, Johnson AK, Crowe JE Jr, Graham BS. Identification of an H-2Db-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus. Virology 2005; 337:335-343.
  126. Peebles RS, Hashimoto K, Sheller JR, Morrow JD, Ji S, Elias J, Goleniewska K, O’Neal J, Mitchell DB, Graham BS, Zhou W. Allergen-induced airway hyperresponsiveness mediated by cyclooxygenase inhibition is not dependent on 5-lipoxygenase or IL-5, but is IL-13 dependent. Journal of Immunology 2005; 175:8253-8259.
  127. Khurana S, Needham J, Mathieson B, Chavez IR, Catanzaro AT, Bailer RT, Kim J, Polonis V, Cooper DA, Guerin J, Peterson ML, Gurwith M, Nguyen N, Graham BS, Golding H & the HIV Vaccine Trial Network. HIV vaccine trials: A novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies in participants. Journal of Virology 2006; 80:2092-2099.
  128. Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, Manischewitz J, King LR, Hryniewicz A, Trindade CJ, Hassett M, Tsai WP, Venzon D, Nalca A, Vaccari M, Silvera P, Bray M, Graham BS, Golding H, Hooper JW, Franchini G. Subunit recombinant vaccine protects against monkeypox. Journal of Immunology 2006; 177:2552-2564.
  129. Khurana S, Needham J, Park S, Mathieson B, Busch MP, Nemo G, Nyambi P, Zolla-Pazner S, Laal S, Mulenga J, Chomba E, Hunter E, Allen S, McIntyre J, Hewlett I, Lee S, Tang S, Cowan E, Beyrer C, Altfeld M, Yu X, Tounkara A, Koita O, Rodriguez-Chavez IR, Nguyen N, Graham BS, Todd D, Mugenyi P, Ketter N, Fast P, Golding H. HIV-SELECTEST- A novel assay for diagnosis of HIV infections in the face of vaccine generated antibodies: Utility for detection of diverse HIV-1 subtypes. Journal of Acquired Immune Deficiency Syndromes 2006; 43:304-312. (Recommended by Faculty of 1000).
  130. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, Andrews CA, Moodie Z, Gu L, Stein JA, Nabel GJ, Graham BS and the VRC 204 Study Team. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clinical and Vaccine Immunology 2006; 13:1267-1277. Epub 2006 Sep 20.
  131. Graham BS, Koup RA, Roederer M, Bailer, Enama ME, Moodie Z, Martin JE, McCluskey MM, Chakrabarti BK, Lamoreaux L, Andrews CA, Gomez PL, Mascola JR, Nabel GJ, and the VRC 004 Study Team. Phase I safety and immunogenicity evaluation of a multiclade HIV-1 candidate DNA vaccine. Journal of Infectious Diseases 2006; 194:1650-1660. (Recommended by Faculty of 1000).
  132. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L, Martin JE, Novik L, Chakrabarti BK, Butman BT, Gall JGD, King CR, Andrews CA, Sheets R, Gomez PL, Mascola JR, Nabel GJ, Graham BS, and the VRC 006 Study Team. Phase I Safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenoviral vector. Journal of Infectious Diseases 2006; 194:1638-1649. (Recommended by Faculty of 1000).
  133. Johnson JE, Gonzales R, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Modern Pathology 2007; 20:108-119. Epub 2006 Nov 24. (Recommended by Faculty of 1000).
  134. Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, Koup RA, Roederer M, Bailer RT, Moodie Z, Gu L, Yan L, Graham BS. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax® challenge in vaccinia-naïve and vaccinia-immune individuals. Vaccine 2007; 25:1513-1525. Epub 2006 Nov 7.
  135. Russell ND, Graham BS, Keefer M, McElrath MJ, Self S, Deers M, Chiu J, Weinhold K, Montefiori D, Ferrari G, Horton H, Gurunathan S, Baglyos L, Frey S, Goepfert P, Harro C, Buchbinder S, Baden L, Blattner W, Koblin BA, Corey L and the NIAID HIV Vaccine Trials Network. Phase II study of an HIV-1 canarypox vaccine (vcp1452), alone and in combination with rgp120: Negative results fail to trigger a phase III correlates trial. Journal of Acquired Immune Deficiency Syndromes 2007; 44:203-212. Epub 2006 Nov 9.
  136. Zhou W, Hashimoto K, Moore ML, Elias JA, Zhu Z, Durbin J, Colasurdo G, Rutigliano JA, Chiappetta CL, Goleniewska K, O’Neal JF, Graham BS, Peebles RS. IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouse. Microbes and Infection 2006; 8:2880-2889. Epub 2006 Oct 24.
  137. Rutigliano JA, Ruckwardt TJ, Martin JE, Graham BS. Distinct epitope-specific CD8+ T cell phenotypes and functional hierarchy in a hybrid mouse model of respiratory syncytial virus infection. Virology 2007; 362:314-319. Epub 2007 Feb 1.
  138. Tavel JA, Martin JE, Kelly GG, Enama ME, Shen JM, Gomez PL, Andrews CA, Koup RA, Bailer RT, Stein JA, Roederer M, Nabel GJ, Graham BS. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1 seronegative subjects. Journal of Acquired Immune Deficiency Syndromes 2007; 44:601-606. Epub 2007 Feb 22.
  139. Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, Martin JE, Rucker S, Andrews CA, Gomez PL, Mascola JR, Nabel GJ, Graham BS. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007; 25:4085-4092. Epub 2007 Mar 7.
  140. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Harari A, Pantaleo G, Bailer R, Graham BS, Roederer M, Koup RA. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses. Journal of Experimental Medicine 2007; 204:1405-1416. Epub 2007 May 29.
  141. Martin JE, Peirson TC, Hubka S, Rucker S, Gordon IJ, Enama ME, Andrews CA, Xu Q, Davis B, Nason M, Fay M, Koup RA, Roederer M, Bailer RT, Gomez PL, Mascola JR, Chang GJ, Nabel GJ, Graham BS. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults in a phase I clinical trial. Journal of Infectious Diseases 2007; 196:1732-1740.
  142. Eller MA, Eller LA, Opollo MS, Ouma BJ, Oballah PO, Galley L, Karnasuta C, Kim SR, Robb ML, Michael N, Kibuuka H, Wabwire-Mangen F, Graham BS, Birx DL, de Souza MS, Cox JH. Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. Vaccine 2007; 25:7737-7742. Epub 2007 Sep 17.
  143. Nelson S, Jost CA, Xu Q, Ess J, Martin JE, Oliphant T, Whitehead SS, Durbin AP, Graham BS, Diamond MS, Pierson TC. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathogens 2008 May 9; 4(5):e1000060.
  144. Shi W, Huang Y, Sutton-Smith M, Tissot B, Panico M, Morris HR, Dell A, Haslam SM, Boyington J, Graham BS, Yang ZY, Nabel GJ. A filovirus-unique region of ebola virus nucleoprotein confers aberrant migration and mediates its incorporation into virions. Journal of Virology 2008; 82:6190-6199. Epub 2008 Apr 16.
  145. Johnson TR, Rothenberg ME, Graham BS. Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. Journal of Leukocyte Biology 2008; 84:748-759. Epub 2008 June 2.
  146. Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, Bailer RT, Gomez PL, Nason M, Mascola JR, Nabel GJ, Graham BS. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 2008; 26:6338-6343. Epub 2008 Sep 26.
  147. Ruckwardt TJ, Bonaparte LK, Nason MC, Graham BS. Regulatory T cells promote early influx of CD8+ T cells in lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. Journal of Virology 2009; 83:3019-3028. Epub 2009 Jan 19.
  148. Liu J, Ruckwardt TJ, Chen M, Johnson TR, Graham BS. Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in murine model. Journal of Virology 2009; 83:4934-4941.  Epub 2009 Mar 4.
  149. Cecchini S, Negrete A, Virag T, Graham BS, Cohen JI, Kotin RM. Evidence of prior exposure to human bocavirus: A retrospective serological study of 404 adult sera in the United States. Clinical and Vaccine Immunology 2009; 16:597-604. Epub Feb 25.
  150. Johnson TR, Rao S, Seder RA, Chen M, Graham BS. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. Vaccine 2009; 27:3045-3052. Epub 2009 Apr 3.
  151. Koup RA, Lamoreaux L, Zarkowsky D, Bailer R, Graham BS, Roederer M. Multiply-deleted replication-defective adenovirus vectors fail to induce measurable vector-specific T cells in human trials. Journal of Virology 2009; 83:6318-6322. Epub 2009 Apr 1.
  152. Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology 2009; 387:414-426. Epub 2009 Mar 17. (Recommended by Faculty of 1000).
  153. Mohapatra S, Park SJ, Boyapalle S, Patsey MK, Graham BS, Blanck G. Human respiratory syncytial virus reduces S-phase cells and increases GADD153 expression in HEp-2 cells. Acta Virologica 2009; 53: 207-211. 
  154. Cheng C, Gall JGD, Nason MC, King CR, Koup RA, Roederer M, McElrath MJ, Morgan CA, Baden L, Churchyard G, Keefer MC, Duerr A, Graham BS, Nabel GJ. Differential specificity and immunogenicity of adenovirus 5 neutralizing antibodies elicited by natural infection or immunization. Journal of Virology 2010; 84:630-638. Epub 2009 Oct 21.
  155. Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, Shaffer D, Eller LA, Kibaya R, Eller MA, Schindler KB, Schuetz A, Millard M, Kroll J, Dally L, Hoelscher M, Bailer R, Cox JH, Marovich M, Birx DL, Graham BS, Michael NL, de Souza MS, Robb ML. A Phase I/II study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus-type 5 boost vaccine in HIV uninfected East Africans (RV 172). Journal of Infectious Diseases 2010; 15:600-607.
  156. McLellan JS, Chen M, Kim A, Yang YP, Graham BS, Kwong PD. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nature Structural & Molecular Biology 2010; 17:248-250. Epub 2010 Jan 24
  157. Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, Larkin BD, Enama ME, Martin JE, Bailer RT, Mascola JR, Nabel GJ, Graham BS, and the VRC 009 and VRC 010 Study Teams. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS ONE 2010; 5(2): e9015. doi:10.1371/journal.pone.0009015.
  158. Freel SA, Lamoreaux L, Chattopadhyay PK, Saunders K, Zarkowsky D, Overman RG, Ochsenbauer C, Edmonds TG, Kappes JC, Cunningham CK, Denny TN, Weinhold KJ , Ferrari G, Haynes BF, Koup RA, Graham BS, Roederer M, Tomaras GD.  Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. Journal of Virology 2010; 84:4998-5006. Epub 2010 Mar 3.
  159. Rosenberg E, Graham BS, Chan E, Bosch R, Stocker V, Maenza J, Markowitz M, Little S, Sax P, Collier A, Nabel GJ, Flynn T, Kuritzkes D, Barouch D and the ACTG 5187 study team. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS ONE 2010: 5(5):e10555.
  160. Graham BS, Kines RC, Corbett KS, Nicewonger J, Johnson TR, Chen M, LaVigne D, Roberts JN, Cuburu N, Schiller JT, Buck CB. Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves potency of DNA vaccination. Mucosal Immunology 2010; 3:475-486. Epub 2010 June 16
  161. Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, Ottinger J, Ferarri G, Montefiori DC, Stablein D, Smith C, Ginsberg R, Eldridge J, Duerr A, Fast P, Haynes BF, and the AIDS Vaccine Evaluation Group. Immunization with cocktail of HIV-derived peptides in Montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS ONE 2010; 5(8): e11995.  doi:10.1371/journal.pone.0011995
  162. Rimoin AW, Mulembakani PD, Johnston S, Smith JOL, Kisalu NK, Lutete TK, Blumberg S, Thomassen HA, Pike BL, Fair JN, Wolfe ND, Shongo RL, Graham BS, Formenty P, Okitolonda E, Hensley L, Meyer H, Wright LL, Muyembe JJ. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proceedings of the National Academy of Sciences 2010; 107:16262-16267. Epub 2010 Aug 30. (Recommended by Faculty of 1000).
  163. Liu J, Ruckwardt TJ, Chen M, Nicewonger JD, Johnson TR, Graham BS. Epitope-specific regulatory CD4 T cells reduce virus-induced illness while preserving CD8 T cell effector function at the site of infection. Journal of Virology 2010; 84:10501-10509. Epub 2010 August 4.
  164. Ruckwardt TJ, Luongo C, Malloy AMW, Liu J, Chen M, Collins PL, Graham BS. Responses against a subdominant CD8+ T cell epitope protect against immunopathology caused by a dominant epitope. Journal of Immunology 2010; 185:4673-4680. Epub 2010 Sep 10.
  165. Chen M, Chang JS, Nason M, Rangel D, Gall JG, Graham BS, Ledgerwood JE. A flow cytometry based assay to assess RSV specific neutralizing antibody is reproducible, efficient and accurate. Journal of Immunological Methods 2010; 362:180-184. Epub 2010 Aug 19.
  166. Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, Adams EM, Graham BS, Koup RA, Bailer RT, Smith C, Dally L, Farah B, Anzala O, Muvunyi CM, Bizimana J, Tarragona T, Bergin PJ, Hayes P, Ho M, Loughran K, Komaroff W, Stevens G, Thomson H, Boaz MJ, Cox JH, Schmidt C, Gilmour J, Nabel GJ, Fast P, Bwayo J. Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS ONE 2010 Sep 21; 5(9);e12873.
  167. McLellan JS, Chen M, Chang JS, Yang YP, Kim A, Graham BS, Kwong PD. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. Journal of Virology 2010; 84:12236-12244. Epub 2010 Sep 29.
  168. Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, McElrath MJ, and the NIAID HIV Vaccine Trials Network. Immunization with a single dose of recombinant adenovirus type 5 HIV-1 vaccine induces strong, durable immune responses in persons without pre-existing neutralizing antibodies against the vector (HVTN 054). PLoS ONE 2010; 5(10):e13579.
  169. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer RT, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS and the VRC 205 Study Team. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010; 29:304-313.  Epub 2010 Oct 27.
  170. Billam P, Bonaparte KL, Liu J, Ruckwardt TJ, Chen M, Ryder AB, Wang R, Dash P, Thomas PG, Graham BS. T cell receptor clonotype influences epitope hierarchy in the CD8+ T cell response to respiratory syncytial virus infection. Journal of Biological Chemistry 2011; 286:4829-4841. Epub 2010 Nov 30.
  171. Johnson TR, Johnson CN, Corbett KS, Edwards GC, Graham BS. Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus. PLoS ONE 2011 Jan 28; 6(1):e16458.
  172. Ledgerwood JE, Pierson TC, Hubka S, Desai N, Rucker S, Gordon IJ, Enama ME, Xu Q, Nason MC, Gu W, Bundrant N, Koup RA, Bailer RT, Gomez PL, Mascola JR, Nabel GJ, Graham BS  and the VRC 303 Study Team. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. Journal of Infectious Diseases 2011; 203:1396-1404. Epub 2011 Mar 11.
  173. McLellan JS, Correia B, Chen M, Yang YP, Graham BS, Schief WR, Kwong PD Design and characterization of epitope-scaffold immunogens that mimic the motavizumab epitope from respiratory syncytial virus. Journal of Molecular Biology 2011; 409:853-866. Epub 2011 Apr 27.
  174. McLellan JS, Yang YP, Graham BS, Kwong PD. Structure of the respiratory syncytial virus fusion glycoprotein in the post-fusion conformation reveals preservation of neutralizing epitopes. Journal of Virology 2011; 85:7788-7796. Epub 2011 May 25.
  175. Li YX, O’Dell S, Walker LM, Wu XL, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Wycuff D, Ledgerwood JE, Graham BS, Haynes BF, Burton DR, Wyatt RT, Mascola JR. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. Journal of Virology 2011; 85:8954-8967. Epub 2011 Jun 29.
  176. Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Wang M, Gray G, Bekker L-G, Baden L, McElrath MJ, Keefer M, and the NIAID HIV Vaccine Trials Network. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS ONE 2011; 6(8):e21225. Epub 2011 Aug 3.
  177. Baden LR, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobieszczyk M, Kochar N, Tomaras GD, McElrath MJ, Russell N, Brandariz K, Cardinali M, Graham BS, Barouch DH, Dolin R, and the NIAID HIV Vaccine Trials Network 044 Study Team. Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. Journal of Infectious Diseases 2011; 204:1541-1549. Epub 2011 Sep 21.
  178. Judkowski V, Bunying A, Ge F, Appel JR, Law K, Sharma A, Raja Gabaglia C, Norori P, Santos, R, Giulianotti, MA, Slifka MK, Douek DC, Graham BS, Pinilla C. GM-CSF production allows the identification of immunoprevalent antigens recognized by human CD4+ T cells following smallpox vaccination. PLoS ONE 2011; 6(9):e24091. Epub 2011 Sep 9.
  179. Koblin BA, Casapia M, Morgan C, Qin L, Wang ZX, Defawe OD, Baden L, Goepfert P, McElrath MJ, Saavedra L, Lau CY, Graham BS, and The NIAID HIV Vaccine Trials Network. Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: A randomized clinical trial (HVTN 069). PLoS ONE 2011; 6(9):e24517. Epub 2011 Sep 12.
  180. De Rosa SC, Thomas EP, Bui J, Huang Y, Decamp A, Morgan C, Kalams SA, Tomaras GD, Akondy R, Ahmed R, Lau CY, Graham BS, Nabel GJ, McElrath MJ; the National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. Journal of Immunology 2011; 187:3391-3401. Epub 2011 Aug 3.
  181. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, Bailer R, Tumpey TM, Andersen H, Koup RA, Mascola JR, Nabel GJ, Graham BS and the VRC 306 Study Team. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infectious Diseases 2011; 11:916-924. Epub 2011 Oct 3.
  182. Ruckwardt TJ, Malloy AMW, Gostick E, Price D, Dash P, McClaren JL, Thomas PG, Graham BS. Neonatal CD8 T-cell hierarchy is distinct from adults and is influenced by intrinsic T cell properties in respiratory syncytial virus infected mice. PLoS Pathogens 2011; 7(12):e1002377. Epub 2011 Dec 1.
  183. Johnson TR, McLellan JS, Graham BS. Respiratory syncytial virus G glycoprotein interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2. Journal of Virology 2012; 86:1339-1347. Epub 2011 Nov 16.
  184. Gordon SN, Kines RC, Kutsyna G, Ma ZM, Hryniewicz A, Roberts JN, Fenizia C1, Hidajat R, Brocca-Cofano E, Cuburu N, Buck CB, Bernardo ML, Robert-Guroff M, Miller CJ, Graham BS, Lowy DR, Schiller JT, Franchini G. Targeting the vaginal mucosa with human papillomavirus pseudovirions vaccines delivering simian immunodeficiency virus DNA. Journal of Immunology 2012; 188:714-723 Epub 2011 Dec 14.
  185. Schmidt C, Smith C, Barin B, Bakhtyari A, Bart PA, Bekker LG, Chomba E, Clumeck N, Ho D, Hoosen A, Jaoko W, Kaleebu P, Karita E, Keefer MC, van Lunzen J, McMichael A, Mehendale S, Peters B, Ramanathan V, Robinson A, Rockstroh J, Vardas E, Vets E, Weber J, Graham BS, Than S, Excler JL, Kochhar S, Ho M, Heald A, Fast PE. Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. Human Vaccines and Immunotherapy 2012; 8:630-638. Epub 2012 May 1.
  186. Ledgerwood JE, Hu Z, Gordon IJ, Yamshchikov G, Enama ME, Hubka S, Bailer R, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS, and the VRC 304 and VRC 305 Study Teams. H5 DNA influenza vaccination is immunogenic by intradermal and intramuscular routes in humans. Clinical and Vaccine Immunology 2012; 19:1792-1797. doi: 10.1128/CVI.05663-11. Epub 2012 Sep 5.
  187. Cuburu N, Graham BS, Buck CB, Kines RC, Pang YS, Day PM, Lowy DR, Schiller JT. Intravaginal immunization with HPV vectors induces memory intraepithelial CD103+CD8+ T-cells in the mouse cervicovaginal mucosa. Journal of Clinical Investigation 2012; 122:4606-4620. doi: 10.1172/JCI63287. Epub 2012 Nov 12.
  188. Casazza JP, Bowman K, Adzaku S, Smith EC, Enama M, Bailer R, Price D, Gostick E, Gordon I, Nason M, Roederer M, Andrews CA, Maldarelli FM, Weigand A, Kearney MF, Ledgerwood JE, Graham BS, Koup RA, and the VRC 101 Study Team. Increased HIV-Specific Response after Vaccination with a DNA prime, rAd5 Boost Vaccination Regimen. Journal of Infectious Diseases 2013; 207:1829-1840. doi: 10.1093/infdis/jit098. Epub 2013 Apr 11.
  189. Ledgerwood JE, Zephir K, Hu ZH, Wei CJ, Chang LJ, Enama ME, Hendel CS, Sitar S, Bailer RT, Koup RA, Mascola, Nabel GJ, Graham BS, and the VRC 310 Study Team. Prime-boost interval matters: A randomized phase I study to identify the minimum interval to observe the H5 DNA influenza vaccine priming effect. Journal of Infectious Diseases 2013; 208:418-422. doi: 10.1093/infdis/jit180. Epub 2013 Apr 30.
  190. Khurana S, Wu J, Dimitrova M, King LR, Manischewitz J, Graham BS, Ledgerwood JE, Golding H. DNA priming prior to H5N1 inactivated influenza vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. Journal of Infectious Diseases 2013; 208:413-417. doi: 10/1093/infdis/jit178. Epub 2013 Apr 30.
  191. Graham BS, Enama ME, Nason MC, Gordon IJ, Peel SA, Ledgerwood JE, Plummer SA, Mascola JR, Bailer RT, Roederer M, Koup RA, Nabel GJ, and the VRC 008 Study Team. DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS ONE 2013; 8:e59340. doi: 10.1371/journal.pone.0059340. Epub 2013 Apr 8. (Recommended by Faculty of 1000).
  192. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 2013; 340:1113-1117. Epub 2013 Apr 25. (Recommended by Faculty of 1000). (selected with #200 for one of 10 runner-up breakthroughs of the year in Science).
  193. Hertz T, Ahmed H, Friedrich DP, Casimiro DR, Self SG, Corey L, McElrath MJ, Buchbinder S, Horton H, Frahm N, Robertson MN, Graham BS, Gilbert P. HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. PLoS Pathogens 2013; 9(6):e1003404. doi: 10.127/journal.ppat.1003404. Epub 2013 Jun 20.
  194. Johnson TR, Rangel D, Graham BS, Brough DE, Gall JG. Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Molecular Therapy 2013; 178:500-506. doi:10.1038/mt.2013.142. Epub 2013 Jun 10.
  195. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li ML, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH, Hendel CS, Novik L, Costner PJM, Mendoza FH, Saunders JG, Nason MC, Richardson JH, Murphy J, Davidson SA, Richie TL, Sedegah M, Sutamihardja A, Fahle GA, Lyke KE, Laurens MB, Roederer M, Tewari K, Epstein JE, Sim BKL, Ledgerwood JE, Graham BS (co-senior author), Hoffman SL for the VRC 312 Study Team. Protection against malaria by intravenous immunization with a non-replicating sporozoite vaccine. Science 2013; 341:1359-1365. doi: 10.1126/science.1241800. Epub 2013 Aug 8.
  196. Hillyer P, Raviv N, Gold DM, Dougherty D, Liu J, Johnson TR, Graham BS, Rabin RL. Subtypes of type I IFN differentially enhance cytokine expression by sub-optimally stimulated CD4+ T cells. European Journal of Immunology 2013 Sep 9. doi: 10.1002/eji.201243288.
  197. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB on behalf of the HIV Vaccine Trials Network 505 Study Team. Efficacy trial of a DNA/rAd5 HIV preventive vaccine. New England Journal of Medicine 2013; 369:2083-2092. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7.
  198. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones G, Yang YP, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GW, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng ZZ, Xia NS, Ko SY, Todd JP, Rao S, Graham BS (co-communicating author), Kwong PD. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013; 342:592-598. doi: 10.1126/science.1243283. Epub 2013 Nov 1 (Recommended by Faculty of 1000) (selected with #194 for one of 10 runner-up breakthroughs of the year in Science; International Society for Vaccines Paper of the Year, 2013).
  199. Whittle JR, Wheatley AK, Wu L, Lingwood D, Wei CJ, Ma SS, Narpala SR, Yassine H, Ledgerwood JE, Graham BS, McDermott AB, Koup RA, Nabel GJ. Structure-based design of hemagglutinin for analysis of the antibody response to influenza. Journal of Virology 2014; 88:4047-4057. Epub 2014 Feb 5.
  200. Schief WR, Correia BE, Bates JT, Loomis RJ, Baneyx G, Jardine JG, Rupert P, Carrico C, Correnti C, Kalyuzhniy O, Vittal V, Connell MJ, Stevens E, Schroeter A, Chen M, MacPherson S, Serra AM, Adachi Y, Holmes MA, Li Y, Klevit RE, Graham BS, Wyatt RT, Baker D, Strong RK, Crowe JE Jr, Johnson PR. Proof of principle for epitope-focused vaccine design. Nature 2014 Feb 5. doi: 10.1038/nature12966.
  201. Liu J, Cao S, Peppers G, Kim SH, Graham BS. Clonotype-specific avidity influences the dynamics and hierarchy of virus-specific regulatory and effector CD4+ T-cell responses. European Journal of Immunology 2014 Jan 13. doi: 10.1002/eji.201343766.
  202. Ruckwardt TJ, Malloy AMW, Morabito KM, Graham BS. Quantitative and qualitative deficits in neonatal lung migratory dendritic cells impact the generation of the CD8+ T cell response. PLoS Pathogens 2014 Feb 13;10(2):e1003934. doi: 10.1371/journal.ppat.1003934.
  203. Enama ME, Ledgerwood JE, Novik L, Nason MC, Gordon IJ, Holman L, Bailer RT, Roederer M, Koup RA, Mascola JR, Nabel GJ, Graham BS, and the VRC 011 Study Team. Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (IM), subcutaneous (SC) and intradermal (ID) administration (VRC 011). PLoS ONE 2014 Mar 12;9(3):e91366. doi: 10.1371/journal.pone.0091366.
  204. Kiss G, Holl JM, Williams GM, Alonas E, Vanover D, Lifland AW, Gudheti M, Guerrero-Ferreira RC, Nair V, Yi H, Graham BS, Santangelo PJ, Wright ER. Structural analysis of respiratory syncytial virus reveals the position of M2-1 between the matrix protein and the ribonucleoprotein complex. Journal of Virology 2014; 88:7602-7617. Epub 2014 Apr 23.
  205. Bar-Haim E, Erez N, Malloy AMW, Graham BS, Ruckwardt TJ. CD8+ TCR transgenic strains expressing public versus private TCR targeting the respiratory syncytial virus KdM282-90 epitope demonstrate similar functional profiles. PLoS ONE 2014 Jun 4;9(6):e99249. doi: 10.1371/journal.pone.0099249.
  206. Manrique A, Adams E, Barouch D, Fast P, Graham BS, Kim J, Kublin JG, McCluskey M, Pantaleo G, Robinson HL, Russell N, Snow W, Johnston MI. The Immune space: A concept and template for rationalizing vaccine development. AIDS Research and Human Retroviruses Epub 2014 Jun 26
  207. Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, Yamshchikov G, Sarwar UN, Hu ZH, Enama ME, Bailer RT, Koup RA, Schwartz RM, Akahata W, Nabel GJ, Mascola JR, Pierson TC, Graham BS, Ledgerwood JE, and the VRC 311 Study Team. Chikungunya virus-like particle vaccine elicits neutralizing antibodies in healthy adults in a phase I dose escalation clinical trial. Lancet 2014 Aug 14. pii: S0140-6736(14)61185-5. doi: 10.1016/S0140-6736(14)61185-5.
  208. Sarwar UN, Novik L, Enama ME, Plummer SA, Koup RA, Nason MC, Bailer RT, McDermott AB, Roederer M, Mascola JR, Ledgerwood JE, Graham BS, and the VRC 015 Study Team. Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial. PLoS ONE 2014 Sep 29;9(9):e106240. doi: 10.1371/journal.pone.0106240.
  209. Bart PA, Huang Y, Karuna S, Kochar N, Allen MA, Chappuis S, Gaillard J, Hural J, Liao HX, Haynes BF, Graham BS, McElrath MJ, Tomaras GD, Montefiori DC, Pantaleo G, Frahm N and the NIAID HIV Vaccine Trials Network. NYVAC is better as a boost than a prime in combination with Ad5 for inducing HIV-specific cellular and humoral responses in humans (HVTN 078). Journal of Clinical Investigation 2014 Oct 1. pii: 75894. doi: 10.1172/JCI75894.
  210. Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, Wu X, Zhu J, Boyington JC, Chen X, Shi W, Yang ZY, Doria-Rose NA, McKee K, O'Dell S, Schmidt SD, Chuang GY, Druz A, Soto C, Yang Y, Zhang B, Zhou T, Todd JP, Lloyd KE, Eudailey J, Roberts KE, Donald BR, Bailer RT, Ledgerwood JE, NISC Comparative Sequencing Program, Mullikin JC, Shapiro L, Koup RA, Graham BS, Nason MC, Connors M, Haynes BF, Rao SS, Roederer M, Kwong PD, Mascola JR, Nabel GJ. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. Journal of Virology 2014 Aug 20. pii: JVI.02213-14.
  211. Herrin DM, Coates EE, Costner PJ, Kemp TH, Nason MC, Saharia KK, Pang Y, Sarwar UN, Holman L, Enama ME, Yamshchikov G, Koup RA, Pang YY, Seder RA, Schiller JT, Graham BS, Pinto LA, Ledgerwood JE, and the VRC 902 Team. Adaptive and innate immune responses of licensed vaccines for human papillomavirus. Human Vaccines and Immunotherapeutics 2014; 10:3446-54. doi: 10.4161/hv.34408.
  212. Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, Sitar S, Gordon IJ, Plummer SA, Holman LA, Hendel CA, Yamshchikov G, Roman F, Nicosia A, Colloca S, Cortese R, Bailer RT, Schwartz RM, Roederer M, Mascola JR, Koup RA, Sullivan NJ, Graham BS, and the VRC 207 Study Team. Chimpanzee adenovirus vector Ebola vaccine – Preliminary report. New England Journal of Medicine 2014 Nov 26. Final report NEJM 2017;
  213. Sarwar UN, Costner P, Enama ME, Berkowitz N, Hu Z, Hendel CS, Sitar S, Plummer S, Bailer RT, Gomez PL, Koup RA, Mascola JR, Nabel GJ, Sullivan NJ, Graham BS, Ledgerwood JE, and the VRC 206 Study Team. DNA vaccines encoding Ebola and Marburg virus wild-type glycoproteins are safe and immunogenic in a phase I clinical trial. Journal of Infectious Diseases 2015 Feb 15; 211:549-57. doi: 10.1093/infdis/jiu511. Epub 2014 Sep 14.
  214. Gordon SN, Doster MN, Kines RC, Keele BF, Brocca-Cofano E, Guan Y, Pegu P, Liyanage NP, Vaccari M, Cuburu N, Buck CB, Ferrari G, Montefiori D, Piatak M Jr, Lifson JD, Xenophontos AM, Venzon D, Robert-Guroff M, Graham BS, Lowy DR, Schiller JT, Franchini G. Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia. Journal of Immunology 2014 Dec 15; 193:6172-83. doi: 10.4049/jimmunol.1401504. Epub 2014 Nov 14.
  215. Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, Costner P, Sitar S, Glover D, Hu ZH, Joshi G, Stanley D, Kunchai M, Eller LA, Bailer RT, Koup RA, Nabel GJ, Mascola JR, Sullivan NJ, Graham BS, Roederer M, Michael NL, Robb ML, Ledgerwood JE, and the RV247 Study Team. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1B, randomised, double-blind, placebo-controlled clinical trial. Lancet 2014 Dec 22. pii: S0140-6736(14)62385-0. doi: 10.1016/S0140-6736(14)62385-0.
  216. Rampling T, Ewer K, Bowyer G, Wright D, Imoukhuede EB, Payne R, Hartnell F, Gibani M, Bliss C, Minhinnick A, Wilkie M, Venkatraman N, Poulton I, Lella N, Roberts R, Sierra-Davidson K, Krähling V, Berrie E, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Becker S, Graham BS, Koup RA, Levine MM, Moorthy V, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV. A monovalent chimpanzee adenovirus Ebola vaccine - Preliminary report. New England Journal of Medicine 2015 Jan 28.
  217. Kines R, Zarnitsyn V, Corbett KS, Johnson TR, Nicewonger J, Schiller JT, Prausnitz M, Graham BS. DNA vaccination with human papillomavirus (HPV) pseudovirus (PsV)-encapsidated plasmids delivered by microneedles. PLoS ONE 2015 Mar 18; 10(3):e0120797. doi: 10.1371/journal.pone.0120797.
  218. Crank MC, Gordon IJ, Yamshchikov GV, Sitar S, Hu Z, Enama ME, Holman LA, Bailer RT, Pearce MB, Koup RA, Mascola JR, Nabel GJ, Tumpey TM, Schwartz, RM, Graham BS, Ledgerwood JE and the VRC 308 Study Team. Phase 1 study of pandemic H1 DNA vaccine in healthy adults. PLoS ONE 2015 Apr 17; 10(4):e0123969. doi: 10.1371/journal.pone.0123969.
  219. Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Tshiani Mbaya O, Zhou Y, Stanley DA, Bliss RL, Cebrik D, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey Jr. RT, Thomas SJ, for the rVSVΔG-ZEBOV-GP Study Group. A recombinant vesicular stomatitis virus Ebola vaccine-Preliminary report. New England Journal of Medicine 2015 Apr 1.
  220. Ledgerwood JE, Bellamy AR, Belshe R, Bernstein DI, Edupuganti S, Patel SM, Renehan P, Zajdowicz T, Schwartz R, Koup R, Bailer RT, Yamshchikov GV, Enama ME, Sarwar U, Larkin B, Graham BS; VRC 701 study team. DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial. PLoS One. 2015 May 7; 10(5):e0125914. doi: 10.1371/journal.pone.0125914.
  221. Stewart-Jones GBE, Thomas PV, Chen M, Druz A, Joyce MG, Kong WP, Sastry M, Soto C, Yang YP, Zhang B, Chen L, Chuang GY, Georgiev IS, McLellan JS, Srivatsan S, Zhou TQ, Baxa U, Mascola JR, Graham BS, Kwong PD. A cysteine zipper stabilizes a pre-fusion F glycoprotein vaccine for respiratory syncytial virus. PLoS One. 2015 Jun 22;10(6):e0128779.
  222. Wheatley AK, Whittle JRR, Ma SS, Narpala SR, Matus-Nicodemos RA, Bailer RT, Nabel GJ, Graham BS, Ledgerwood JE, Koup RA, McDermott AB. H5N1 vaccine-elicited memory B cells are genetically constrained by the IGHV locus in the recognition of a neutralizing epitope in the HA stem. Journal of Immunology 2015 Jul 15;195(2):602-10. doi: 10.4049/jimmunol.1402835. Epub 2015 Jun 15.
  223. Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou TQ, Yassine HM, Kanekiyo M, Yang ZY, Chen XJ, Becker MM, Freeman MC, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS. Evaluation of candidate vaccine approaches for MERS-CoV. Nature Communications 2015 Jul 28;6:7712. doi: 10.1038/ncomms8712.
  224. Ledgerwood JE, Hu Z, Costner P, Yamshchikov G, Enama ME, Plummer S, Hendel CS, Holman L, Larkin B, Gordon I, Bailer RT, Poretz DM, Sarwar U, Kabadi A, Koup R, Mascola JR, Graham BS; VRC 307 and VRC 309 Study Teams. Phase I Clinical Evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. Contemporary Clinical Trials 2015 Aug 11. pii: S1551-7144(15)30064-1. doi: 10.1016/j.cct.2015.08.006.
  225. Kanekiyo M, Bu W, Joyce MG, Whittle JR, Meng G, Baxa U, Yamamoto T, Foulds KE, Letukas VA, Todd JP, Ko SY, Rao SS, Roederer M, Koup RA, Rossmann MG, Mascola JR, Graham BS, Cohen JI, Nabel GJ. Self-assembled nanoparticulate Epstein-Barr virus major envelope immunogens elicit potently neutralizing antibody. Cell 2015 Aug 27;162(5):1090-100. doi: 10.1016/j.cell.2015.07.043. Epub 2015 Aug 13.
  226. Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, DeZure A, Gordon I, Plummer S, Hendel CS, Lynch R, Conan-Cibotti M, Sitar S, Bailer RT, Narpala S, McDermott A, Louder M, O'Dell S, Mohan S, Pandey JP, Schwartz RM, Hu Z, Koup RA, Capparelli E, Mascola JR, Graham BS, and the VRC 602 Study Team. Safety, pharmacokinetics, and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clinical and Experimental Immunology 2015 Sep 1. doi: 10.1111/cei.12692.
  227. Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP, Gallagher JR, Wang LS, Zhang Y, Joyce MG, Lingwood D, Moin SM, Andersen H, Okuno Y, Rao SS, Harris AK, Kwong PD, Mascola JR, Nabel GJ, Graham BS. Hemagglutinin stem nanoparticle generates heterosubtypic influenza protection. Nature Medicine 2015 Sep; 21(9):1065-1070. doi: 10.1038/nm.3927. Epub 2015 Aug 24. (Faculty of 1000)
  228. Liang B, Surman S, Amaro-Carambot E, Kabatova B, Mackow N, Lingemann M, Yang L, McLellan JS, Graham BS, Kwong PD, Schaap-Nutt A, Collins PL, Munir S. Enhanced neutralizing antibody response induced by respiratory syncytial virus pre-fusion F protein expressed by a vaccine candidate. Journal of Virology 2015 Sep 15; 89(18):9499-510. doi: 10.1128/JVI.01373-15. Epub 2015 Jul 8.
  229. Gilman MS, Moin SM, Mas V, Chen M, Patel NK, Kramer K, Zhu Q, Kabeche SC, Kumar A, Palomo C, Beaumont T, Baxa U, Ulbrandt ND, Melero JA, Graham BS, McLellan JS. Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathogens 2015 Jul 10; 11(7):e1005035.
  230. Williams WB, Liao HX, Moody MA, Kepler TB, Alam M, Gao F, Wiehe K, Trama AM, Jones K, Zhang R, Song H, Marshall DJ, Whitesides J, Sawatzki K, Hua A, Liu P, Tay MZ, Seaton K, Shen Z, Foulger A, Lloyd KE, Parks R, Pollara J, Ferrari G, Yu JS, Vandergrift N, Montefiori DC, Sobieszczyk ME, Hammer S, Karuna S, Gilbert P, Grove D, Grunenberg, McElrath MJ, Mascola JR, Koup R, Corey L, Nabel GB, Morgan C, Churchyard G, Maenza J, Keefer M, Graham BS, Baden LR, Tomaras GD, Haynes BF. Diversion of HIV-1 vaccine-induced immunity by gp41-intestinal microbiota cross-reactive antibodies. Science 2015 Aug 14; 349(6249):aab1253. doi: 10.1126/science. aab1253. Epub 2015 Jul 30.
  231. Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, Kumar A, Yassine HM, Moin SM, Killikelly AM, Chuang GY, Druz A, Georgiev IS, Rundlet EJ, Sastry M, Stewart-Jones GBE, Yang Y, Zhang B, Nason MC, Capella C, Peeples ME, Ledgerwood JE, McLellan JS, Kwong PD, Graham BS. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Science Translational Medicine 2015 Oct 14; 7(309):309ra162. doi: 10.1126/scitranslmed.aac4241.
  232. Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB. Effect of rAd5-vector HIV-1 preventive vaccines on HIV-1 acquisition: A participant-level meta-analysis of randomized trials. PLoS One. 2015 Sep 2; 10(9):e0136626.
  233. Fuchs JD, Bart PA, Frahm N, Morgan C, Gilbert PB, Kochar N, DeRosa SC, Tomaras GD, Wagner TM, Baden LR, Koblin BA, Rouphael NG, Kalams SA, Keefer MC, Goepfert PA, Sobieszczyk ME, Mayer KH, Swann E, Liao HX, Haynes BF, Graham BS, McElrath MJ; NIAID HIV Vaccine Trials Network. Safety and immunogenicity of a recombinant adenovirus serotype 35-vectored HIV-1 vaccine in adenovirus serotype 5 seronegative and seropositive individuals. Journal of AIDS Clinical Research 2015 May; 6(5). pii: 461. Epub 2015 May 23.
  234. Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X; HVTN 083 Study Group, and the NIAID HIV Vaccine Trials Network. Vaccination with heterologous HIV envelope sequences and heterologous adenovirus vectors increases T cell responses to conserved regions (HVTN 083). Journal of Infectious Diseases Epub 2015 Oct 15.
  235. Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, Sztein MB, Wahid R, Campbell JD, Kieny MP, Moorthy V, Imoukhuede EB, Rampling T, Roman F, De Ryck I, Bellamy AR, Dally L, Mbaya OT, Ploquin A, Zhou Y, Stanley DA, Bailer R, Koup RA, Roederer M, Ledgerwood J, Hill AV, Ballou WR, Sullivan N, Graham B, Levine MM. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases 2015 Nov 3 doi: 10.1016/S1473-3099(15)00362-X.
  236. Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, Enama ME, Plummer S, Holman L, Hendel CS, Gordon I, Casazza J, Conan-Cibotti M, Migueles SA, Tressler R, Bailer RT, McDermott A, Narpala S, O’Dell S, Wolf G, Lifson JD, Freemire BA, Gorelick RJ, Pandey JP, Mohan S, Chomont N, Fromentin R, Chun TW, Fauci AS, Schwartz RM, Koup RA, Douek DC, Hu Z, Capparelli E, Graham BS, Mascola JR, Ledgerwood JE, and the VRC 601 Study Team. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Science Translational Medicine 2015 Dec 23;7(319):319ra206. doi: 10.1126/scitranslmed.aad5752.
  237. De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, Thierry AC, Mayor C, Bailer RT, Mbaya OT, Zhou Y, Ploquin A, Sullivan NJ, Graham BS, Roman F, De Ryck I, Ballou WR, Kieny MP, Moorthy V, Spertini F, Genton B. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infectious Diseases 2015 Dec 22; pii: S1473-3099(15)00486-7. doi: 10.1016/S1473-3099(15)00486-7.
  238. Morabito KM, Erez N, Graham BS, Ruckwardt TJ. Phenotype and hierarchy of two transgenic T cell lines targeting the respiratory syncytial virus KdM282-90 epitope is transfer dose-dependent. PLoS One. 2016 Jan 11; 11(1):e0146781. doi: 10.1371/journal. pone.0146781.
  239. Misasi J, Gilman MSA, Kanekiyo M, Gui M, Cagigi A, Mulangu S, Corti D, Ledgerwood JE, Lanzavecchia A, Cunningham J, Muyembe-Tamfun JJ, Baxa U, Graham BS, Xiang Y, Sullivan NJ, McLellan JS. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 2016 Feb 25. pii: aad6117.
  240. Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen A, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ,Trefry JC, Lanzavecchia A, Sullivan NJ. Protective monotherapy against lethal Ebola Virus infection by a potently neutralizing antibody. Science 2016 Feb 25. pii: aad5224.
  241. Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, Corbett KS, Graham BS, McLellan JS, Ward AB. Prefusion structure of a human coronavirus spike protein. Nature 2016 Mar 3; 531(7592):118-21. doi: 10.1038/nature17200.
  242. Hessell AJ, Jaworski JP, Epson E, Matsuda K, Pandey S, Kahl C, Reed J, Sutton WF, Hammond KB, Cheever TA, Barnette PT, Legasse A, Planer S, Stanton J, Pegu A, Chen X, Wang K, Siess D, Burke D, Axthelm MK, Lewis A, Hirsch VM, Graham BS, Mascola JR, Sacha JB, Haigwood NL. Early short-term treatment with neutralizing human monoclonal antibodies intercepts viral reservoir persistence in SHIV-exposed newborn macaques. Nature Medicine 2016 Apr;22(4):362-8. doi: 10.1038/nm.4063. Epub 2016 Mar 21.
  243. Liu J, Haddad EK, Marceau J, Morabito KM, Rao SS, Filali A, Sekaly RP, Graham BS. A Numerically subdominant CD8 T cell response to matrix protein of respiratory syncytial virus controls infection with limited immunopathology. PLoS Pathogens 2016 Mar 4; 12(3):e1005486. doi: 10.1371/journal.ppat.1005486.
  244. Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, Biedenkopf N, Krähling V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbé G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra-Davidson K, Powlson J, Berrie E, Tedder R, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, Levine MM, Volkmann A, Chaplin P, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. New England Journal of Medicine 2016; 374:1635-46. doi: 10.1056/NEJMoa1411627. Epub 2015 Jan 28.
  245. Ishizuka AS, Lyke KE, DeZure A, Berry A, Richie TL, Mendoza FH, Enama ME, Gordon IJ, Zephir KL, Holman LA, James ER, Billingsley PF, Gunasekera A, Chakravarty S, Manoj A, Li ML, Ruben AJ, Li T, Eappen AG, Stafford RE, Natasha KC, Murshedkar T, Decederfelt H, Plummer SH, Hendel CS, Novik L, Costner PJM, Saunders JG, Laurens MB, Plowe CV, Flynn B, Whalen W, Todd JP, Noor J, Rao S, Sierra-Davidson K, Kemp M, Fahle GA, Mikolajczak SA, Fishbaugher M, Sack BK, Kappe S, Davidson SA, Garver L, Nason MC, Graham BS, Roederer M, Sim BKL, Hoffman SL, Ledgerwood JE, Seder RA, for the VRC 312 and VRC 314 Study Teams. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nature Medicine 2016 May 9. doi: 10.1038/nm.4110.
  246. Morabito KM, Ruckwardt TR, Redwood AJ, Moin SM, Price DA, Graham BS. Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung. Mucosal Immunology 2017 Mar;10(2):545-554. doi: 10.1038/mi.2016.48. Epub 2016 May 25.
  247. Boyington JC, Joyce MG, Sastry M, Stewart-Jones GBE, Chen M, Kong WP, Ngwuta J, Thomas PV, Tsybovsky Y, Yang Y, Zhang B, Chen L, Druz A, Georgiev IS, Ko K, Zhou T, Mascola JR, Graham BS, Kwong PD. Structure-based design of head-only fusion glycoprotein immunogens for respiratory syncytial virus. PLoS ONE 2016 Jul 27; 11(7):e0159709. doi: 10.1371/journal.pone.0159709.
  248. Joyce MG, Wheatley AK, Thomas PV, Chuang GY, Soto C, Bailer RT, Druz A, Georgiev IS, Kong WP, Leung K, Narpala SN, Prabhakaran MS, Yang ES, Zhang B, Zhang Y, Asokan M, Boyington JC, Bylund T, Darko S, Kanekiyo M, Lees CR, Ransier A, Shen H, Wang L, Whittle JR, Wu X, Yassine HM, Tsybovsky Y, Baxa U, NISC Comparative Sequencing Program, Mullikin JC, Douek DC, Graham BS, Koup RA, Ledgerwood JE, Roederer M, Shapiro L, Kwong PD, Mascola JR, McDermott AB. Vaccine induction and biomarker utility of convergent antibodies that neutralize group 1 and 2 influenza A viruses. Cell 2016 Jul 28; 166(3):609-23. doi: 10.1016/j.cell.2016.06.043. Epub 2016 Jul 21.
  249. Joyce MG, Zhang B, Ou L, Chen M, Chuang GY, Druz A, Kong WP, Lai YT, Rundlet EJ, Tsybovsky Y, Yang Y, Georgiev IS, Lees CR, Sastry M, Stewart-Jones GBE, Thomas PV, Van Galen JG, Baxa U, Mascola JR, Graham BS, Kwong PD. Iterative structure-based improvement of stability and immunogenicity of a fusion glycoprotein vaccine for respiratory syncytial virus. Nature Structure Molecular Biology 2016 Aug 1. doi: 10.1038/nsmb.3267.
  250. Rostad CA, Stobart CC, Gilbert BE, Pickles RJ, Hotard AL, Meng J, Blanco JC, Moin SM, Graham BS, Piedra PA, Moore ML. A recombinant respiratory syncytial virus vaccine candidate attenuated by a low-fusion F protein is immunogenic and protective against challenge in cotton rats. Journal of Virology 2016 Jun 8. pii: JVI.00012-16.
  251. Jacobino SR, Nederend M, Hennus, M, Houben ML, Ngwuta JO, Viveen M, Coenjaerts FEJ, Hack CE, van Neerven RJJ, Graham BS, Bont L, Leusen JHW. Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection. Journal of Allergy and Clinical Immunology 2016 Jun 16. pii: S0091-6749(16)30496-1. doi: 10.1016/j.jaci.2016.06.001.
  252. Dowd KA, DeMaso CR, Pelc RS, Speer SD, Smith ARY, Goo L, Platt DJ, Mascola JR, Graham BS, Mulligan MJ, Diamond MS, Ledgerwood JE, Pierson TC. Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype. Cell Reports 2016 Aug 9; 16(6):1485-91. doi: 10.1016/j.celrep.2016.07.049. Epub 2016 Jul 29.
  253. Liang B, Ngwuta JO, Herbert R, Swerczek J, Dorward DM, Amaro-Carambot E, Mackow N, Kabatova B, Lingemann M, Surman S, Yang L, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Schaap-Nutt A, Collins PL, Munir S. Packaging and prefusion stabilization separately and additively increase the quantity and quality of RSV-neutralizing antibodies induced by respiratory syncytial virus (RSV) fusion protein expressed by a parainfluenza vector. Journal of Virology 2016 Aug 31. pii: JVI.01196-16.
  254. Francica JR, Lynn GM, Laga R, Joyce MG, Ruckwardt TJ, Moribito KM, Chen M, Chaudhuri R, Zhang B, Sastry M, Ko K, Choe M, Pechar M, Georgiev IS, Kueltzo LA, Seymour LW, Mascola JR, Kwong PD, Graham BS, Seder RA. Thermo-responsive polymer nanoparticles co-deliver RSV F trimers with a TLR-7/8 adjuvant. Bioconjugate Chemistry 2016 Oct 19; 27(10):2372-2385.
  255. Goo L, Dowd KA, Lin TY, Mascola JR, Graham BS, Ledgerwood JE, Pierson TC. A virus-like particle vaccine elicits broad neutralizing antibody responses in humans to all Chikungunya virus genotypes. Journal of Infectious Diseases 2016 Nov 15; 214(10):1487-1491.
  256. Killikelly AM, Kanekiyo M, Graham BS. Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. Scientific Reports 2016 Sep 29; 6:34108.
  257. Dowd KA, Ko SY, Morabito KM, Yang ES, Pelc RS, DeMaso CR, Castilho LR, Abbink P, Boyd M, Nityanandam R, Gordon DN, Gallagher J, Chen XJ, Todd JP, Tsybovsky Y, Harris A, Huang YS, Higgs S, Vanlandingham DL, Andersen H, Lewis MG, De La Barrera R, Eckels KH, Jarman RG, Nason MC, Barouch DH, Roederer M, Kong WP, Mascola JR, Pierson TC, Graham BS. Rapid development of a DNA vaccine for Zika virus. Science 2016; 354(6309):237-240. doi:10.1126/science.aai3197.
  258. Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V, Kose N, Blum DL, Hughes LJ, Satheshkumar PS, Townsend MB, Kondas AV, Reed Z, Weiner Z, Olson VA, Hammarlund E, Raue HP, Slifka MK, Slaughter JC, Graham BS, Edwards KM, Eisenberg RJ, Cohen GH, Joyce S, Crowe JE Jr. Cross-neutralizing and protective human antibody specificities to poxvirus infections. Cell 2016 Oct 20;167(3):684-694.e9.
  259. Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, Salantes DB, Seamon CA, Scheinfeld B, Kwan RW, Learn GH, Proschan MA, Kreider EF, Blazkova J, Bardsley M, Refsland EW, Messer M, Clarridge KE, Tustin N, Madden PJ, Oden K, O’Dell SJ, Jarocki B, Shiakolas AR, Tressler RL, Doria-Rose NA, Bailer RT, Ledgerwood JE, Caparelli E, Lynch RM, Graham BS, Moir S, Koup RA, Mascola JR, Hoxie JA, Fauci AS, Tebas P, Chun TW. Effect of HIV-specific antibody VRC01 on viral rebound after treatment interruption. New England Journal of Medicine 2016 Nov 24; 375(21):2037-2050.
  260. Stobart CC, Rostad CA, Ke Z, Dillard RS, Hampton CM, Strauss JD, Yi H, Hotard AL, Meng J, Pickles RJ, Sakamoto K, Lee S, Currier MG, Moin S, Graham BS, Boukhvalova MS, Gilbert BE, Blanco JCG, Piedra PA, Wright ER, Moore ML. A live-attenuated RSV vaccine with engineered thermostability is immunogenic despite high attenuation in cotton rats. Nature Communications 2016 Dec 21; 7:13916. doi: 10.1038/ncomms13916.
  261. Gilman MSA, Castellanos CA, Chen M, Ngwuta JO, Goodwin E, Moin S, Mas V, Melero JA, Wright PF, Graham BS, McLellan JS, Walker LM. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Science Immunology 2016 Dec 16;1(6). pii: eaaj1879. doi: 10.1126/sciimmunol.aaj1879.
  262. Crank MC, Wilson EMP, Novik L, Enama ME, Hendel CS, Gu W, Nason MC, Bailer RT, Nabel GJ, McDermott AB, Mascola JR, Koup RA, Ledgerwood JE, Graham BS, and the VRC012 Study Team. Safety and immunogenicity of a rAd35-EnvA prototype HIV-1 vaccine in combination with rAd5-EnvA in healthy adults (VRC 012). PLoS ONE 2016; Nov 15;11 (11):e0166393.
  263. Malloy AMW, Ruckwardt TJ, Morabito KM, Lau-Kilby AW, Graham BS. Pulmonary dendritic cell subsets shape the respiratory syncytial virus-specific CD8+ T cell immunodominance hierarchy in neonates. Journal of Immunology 2017 Jan 1; 198(1):394-403.
  264. Schwarz B, Morabito KM, Ruckwardt TJ, Patterson DP, Avera J, Miettinen HM, Graham BS, Douglas T. Virus-like particles encapsidating respiratory syncytial virus M and M2 proteins induce robust T cell responses. ACS Biomaterials, Science, and Engineering 2016; 2(12):2324-2332. doi: 10.1021.
  265. Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W, Granados A, Greenhouse J, Walker M, Willis E, Yu JS, McGee CE, Sempowski GD, Mui BL, Tam YK, Huang YJ, Vanlandingham D, Holmes VM, Balachandran H, Sahu S, Lifton M, Higgs S, Hensley SE, Madden TD, Hope MJ, Karikó K, Santra S, Graham BS, Lewis MG, Pierson TC, Haynes BF, Weissman D. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 2017 Feb 2. doi: 10.1038/nature21428. (Winner of Bial Award in Biomedicine 2021)
  266. Rossey I, Gilman MSA, Kabeche S, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nature Communications 2017 Feb 13; 8:14158. doi: 10.1038/ncomms14158.
  267. Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, Mulligan MJ, Koblin B, Buchbinder SP, Keefer MC, Adams E, Anude C, Corey L, Sobieszczyk M, Hammer SM, Gilbert PB, McElrath MJ. Higher T cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial. Journal of Infectious Diseases 2017 Feb 12; doi: 10.1093/infdis/jix086.
  268. Lyke K, Ishizuka AS, Berry AB, Chakravarty S, DeZure A, Enama ME, James ER, Billingsley PF, Gunasekera A, Manoj A, Li ML, Ruben AJ, Li T, Eappen AG, Stafford RE, Kc N, Murshedkar T, Mendoza FH, Gordon IJ, Zephir KL, Holman LA, Plummer SH, Hendel CS, Novik L, Costner PJ, Saunders JG, Berkowitz NM, Flynn BJ, Nason MC, Garver LS, Laurens MB, Plowe CV, Richie TL, Graham BS, Roederer M, Sim BK, Ledgerwood JE, Hoffman SL, Seder RA. PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proceedings of the National Academy of Sciences USA 2017 Feb 21; pii: 201615324. doi: 10.1073/pnas.1615324114.
  269. Ruckwardt TJ, Morabito KM, Graham BS. Neonatal mice possess two phenotypically and functionally distinct lung-migratory CD103+ dendritic cell populations following respiratory infection. Mucosal Immunology 2017 Apr 5. doi: 10.1038/mi.2017.28.
  270. Coates EE, Costner PJ, Nason MC, Herrin DM, Conant S, Herscovitch P, Sarwar UN, Holman L, Mitchell J, Yamshchikov G, Koup RA, Graham BS, Millo CM, Ledgerwood JE, and the VRC 900 Study Team. Lymph node activation by PET/CT following vaccination with licensed vaccines for human papillomaviruses. Clinical Nuclear Medicine 2017 May; 42(5):329-334. doi: 10.1097. Epub 2017 Mar 10.
  271. DeZure AD, Coates EE, Hu ZH, Yamshchikov GV, Zephir KL, Plummer SH, Gordon IJ, Crank MC, Bailer RT, Koup RA, Sun X, Tumpey TM, Graham BS, Ledgerwood JE. An avian influenza H7 DNA priming vaccine is safe and immunogenic in a phase I clinical trial. Nature Vaccines 2017 Jun 1; 2:15. doi: 10.1038/s41541-017-0016-6. eCollection 2017.
  272. Leemans A, De Schryver M, Van der Gucht W, Heykers A, Pintelon I, Hotard AL, Moore ML, Melero JA, McLellan JS, Graham BS, de Haan CAM, Broadbent L, Power UF, Cos P, Maes L, Delputte P. Antibody-induced internalization of the human respiratory syncytial virus fusion protein. Journal of Virology 2017 May 3. pii: JVI.00184-17. doi: 10.1128/JVI.00184-17.
  273. Hosken N, Plikaytis B, Trujillo C, Mahmood K, Higgins D, and the Participating Laboratories Working Group (Piedra P, Tamin A, Maleux K, Karron R, Shambaugh C, Graham BS, Shaw C, Cooper D, Boukhvalova M, Walsh E, Khurana S, Beeler J). A multi-laboratory study of diverse RSV neutralization assays indicates feasibility for harmonization with an international standard. Vaccine 2017 May 25; 35:3082-3088. doi:10.1016/j.vaccine.2017.04.053. Epub 2017 May 2.
  274. Zhao M, Zheng ZZ, Chen M, Modjarrad K, Zhang W, Zhan LT, Cao JL, Sun YP, McLellan JS, Graham BS, Xia NS. Discovery of a prefusion RSV F-specific monoclonal antibody that provides greater in vivo protection than the murine precursor of palivizumab. Journal of Virology 2017 Jul 12; 91(15). pii: e00176-17. doi: 10.1128/JVI.00176-17. Print 2017 Aug 1.
  275. Liang B, Ngwuta JO, Surman S, Kabatova B, Liu X, Lingemann M, Liu X, Yang L, Herbert R, Swerczek J, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Collins PL, Munir S. Improved prefusion stability, optimized codon-usage, and augmented virion packaging enhance the immunogenicity of RSV fusion protein in a vectored vaccine candidate. Journal of Virology 2017 Jul 12 ;91(15). pii: e00189-17. doi: 10.1128/JVI.00189-17. Print 2017 Aug 1.
  276. Andrews SF, Joyce MG, Chambers MJ, Gillespie RA, Kanekiyo M, Leung K, Yang ES, Tsybovsky Y, Wheatley AK, Crank MC, Boyington JC, Prabhakaran MS, Narpala SR, Chen X, Bailer RT, Chen G, Coates E, Koup RA, Kwong PD, Mascola JR, Graham BS, Ledgerwood JE, McDermott AB. Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells following H7N9 immunization in humans. Science Immunology 2017 Jul 14; 2(13). pii: eaan2676. doi: 10.1126/sciimmunol.aan2676.
  277. Han Q, Williams WB, Saunders KO, Seaton KE, Wiehe KJ, Vandergrift N, Von Holle T, Trama AM, Parks RJ, Luo K, Gurley TC, Kepler TB, Marshall DJ, Montefiori DC, Sutherland LL, Alam MS, Whitesides JF, Bowman C, Permar SR, Graham BS, Mascola JR, Seed PC, Van Rompay KKA, Tomaras GD, Moody MA, Haynes BF. HIV DNA-adenovirus multiclade Envelope vaccine induces Gp41 antibody immunodominance in Rhesus macaques. Journal of Virology 2017 Aug 9. pii: JVI.00923-17. doi: 10.1128/JVI.00923-17.
  278. Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, Kong WP, Andres EL, Kettenbach AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proceeding of the National Academy of Sciences USA 2017 Aug 14. pii: 201707304. doi: 10.1073/pnas.1707304114.
  279. Liu X, Liang B, Ngwuta J, Liu X, Surman S, Lingemann M, Kwong PD, Graham BS, Collins PL, Munir S. Attenuated human parainfluenza virus type 1 (HPIV1) expressing the respiratory syncytial virus (RSV) fusion F glycoprotein from an added gene: effects of pre-fusion stabilization and packaging of RSV F. Journal of Virology 2017 Aug 23. pii: JVI.01101-17. doi: 10.1128/JVI.01101-17.
  280. deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB. Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. PLoS One. 2017 Nov 17; 12(11):e0185959. doi: 10.1371/journal.pone.0185959.
  281. Shan C, Muruato AE, Jagger BW, Richner J, Nunes BTD, Medeiros DBA, Xie X, Nunes JGC, Morabito KM, Kong WP, Pierson TC, Barrett AD, Weaver SC, Rossi SL, Vasconcelos PFC, Graham BS, Diamond MS, Shi PY. A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. Nature Communications 2017 Sep 22; 8(1):676. doi: 10.1038/s41467-017-00737-8.
  282. Grifoni A, Pham J, Sidney J, O'Rourke PH, Paul S, Peters B, Martini SR, de Silva AD, Ricciardi MJ, Magnani DM, Silveira CGT, Maestri A, Costa PR, de-Oliveira-Pinto LM, de Azeredo EL, Damasco PV, Phillips E, Mallal S, de Silva AM, Collins M, Durbin A, Diehl SA, Cerpas C, Balmaseda A, Kuan G, Coloma J, Harris E, Crowe JE Jr, Stone M, Norris PJ, Busch M, Vivanco-Cid H, Cox J, Graham BS, Ledgerwood JE, Turtle L, Solomon T, Kallas EG, Watkins DI, Weiskopf D, Sette A. Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans. Journal Virology 2017 Oct 4; pii: JVI.01469-17. doi: 10.1128/JVI.01469-17.
  283. Sastry M, Zhang B, Chen M, Joyce MG, Kong WP, Chuang GY, Ko K, Kumar A, Silacci C, Thom M, Salazar AM, Corti D, Lanzavecchia A, Taylor G, Mascola JR, Graham BS, Kwong PD. Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus. PLoS One. 2017 Oct 26;12(10):e0186854. doi: 10.1371/journal.pone.0186854. eCollection 2017.
  284. Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, Ledgerwood JE, Frank I, Sobieszczyk ME, Baden LR, Rodriguez B, Van Tieu H, Tomaras GD, Deal A, Goodman D, Bailer RT, Ferrari G, Jensen R, Hural J, Graham BS, Mascola JR, Corey L, Montefiori DC; HVTN 104 Protocol Team; and the NIAID HIV Vaccine Trials Network. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. PLoS Med. 2017 Nov 14;14(11):e1002435. doi: 10.1371/journal.pmed.1002435.
  285. Tian D, Battles MB, Moin SM, Chen M, Modjarrad K, Kumar A, Kanekiyo M, Graepel KW, Taher NM, Hotard AL, Moore ML, Zhao M, Zheng ZZ, Xia NS, McLellan JS, Graham BS. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nature Communications 2017 Nov 30; 8(1):1877. doi:10.1038/s41467-017-01858-w.
  286. Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS, Berkowitz N, Mendoza F, Saunders JG, Novik L, Hendel CS, Holman LA, Gordon IJ, Cox JH, Edupuganti S, McArthur MA, Rouphael NG, Lyke KE, Cummings GE, Sitar S, Bailer RT, Foreman BM, Burgomaster K, Pelc RS, Gordon DN, DeMaso CR, Dowd KA, Laurencot C, Schwartz RM, Mascola JR, Graham BS, Pierson TC, Ledgerwood JE, Chen GL, and the VRC 319 and VRC 320 study teams. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet 2017 Dec 4. pii: S0140-6736(17)33105-7. doi: 10.1016/S0140-6736(17)33105-7.
  287. Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, Donnell DJ, Bentley C, Sista N, Andrew P, Isaacs A, Huang Y, Zhang L, Capparelli E, Kochar N, Wang J, Eshleman SH, Mayer KH, Magaret CA, Hural J, Kublin JG, Gray G, Montefiori DC, Gomez MM, Burns DN, McElrath J, Ledgerwood J, Graham BS, Mascola JR, Cohen M, Corey L. Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Statistical Communications in Infectious Diseases 2017 Jan;9(1). pii: 20160001. doi: 10.1515/scid-2016-0001.
  288. Fong Y, Shen X, Ashley VC, Deal A, Seaton KE, Yu C, Grant SP, Ferrari G, decamp AC, Bailer RT, Koup RA, Montefiori D, Haynes BF, Sarzotti-Kelsoe M, Graham BS, Carpp LN, Hammer SM, Sobieszczyk M, Karuna S, Swann E, DeJesus E, Mulligan M, Frank I, Buchbinder S, Novak R, McElrath MJ, Kalams S, Keefer M, Frahm NA, Janes HE, Gilbert PB, Tomaras GD. Vaccine-induced antibody responses modify the association between T-cell immune responses and HIV-1 infection risk in HVTN 505. Journal of Infectious Diseases 2018 Jan 8. doi: 10.1093/infdis/jiy008.
  289. Wang B, DeKosky BJ, Timm MR, Lee J, Normandin E, Misasi J, Kong R, McDaniel JR, Delidakis G, Leigh KE, Niezold T, Choi CW, Viox EG, Fahad A, Cagigi A, Ploquin A, Leung K, Yang ES, Kong WP, Voss WN, Schmidt AG, Moody MA, Ambrozak DR, Henry AR, Laboune F, Ledgerwood JE, Graham BS, Connors M, Douek DC, Sullivan NJ, Ellington AD, Mascola JR, Georgiou G. Functional interrogation and mining of natively-paired VH:VL human antibody repertoires. Nature Biotechnology 2018 Jan 8. doi: 10.1038/nbt.4052.
  290. Goo L, DeMaso CR, Pelc RS, Ledgerwood JE, Graham BS, Kuhn RJ, Pierson TC. The Zika virus envelope protein glycan loop regulates virion antigenicity. Virology 2018 Jan 2; 515:191-202. doi: 10.1016/j.virol.2017.12.032.
  291. Gaudinski MR, Coates EE, Houser KV, Chen GL, Yamshchikov G, Saunders JG, Holman LA, Gordon I, Plummer S, Hendel CS, Conan-Cibotti M, Lorenzo MG, Sitar S, Carlton K, Laurencot C, Bailer RT, Narpala S, McDermott AB, Namboodiri AM, Pandey JP, Schwartz RM, Hu Z, Koup RA, Capparelli E, Graham BS, Mascola JR, Ledgerwood JE, and the VRC 606 Study Team. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A phase 1 open-label clinical trial in healthy adults. PLoS Medicine 2018 Jan 24; 15(1): e1002493. doi: 10.1371/journal.pmed.1002493.
  292. Wang L, Shi W, Chappell JD, Joyce MG, Zhang Y, Kanekiyo M, Becker MM, van Doremalen N, Fischer R, Wang N, Corbett KS, Choe M, Mason RD, Van Galen JG, Zhou T, Saunders KO, Tatti KM, Haynes LM, Kwong PD, Modjarrad K, Kong WP, McLellan JS, Denison MR, Munster V, Mascola JR, Graham BS. Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape. Journal of Virology 2018 Mar 7. pii: JVI.02002-17. doi: 10.1128/JVI.02002-17.
  293. Goodwin E, Gilman MSA, Wrapp D, Chen M, Ngwuta JO, Moin SM, Bai P, Sivasubramanian A, Connor RI, Wright PF, Graham BS, McLellan JS, Walker LM. Isolation of recurrent neutralizing antibodies that lack hypermutation from RSV-infected infants. Immunity 2018 Jan 20; 48:339-349. pii: S1074-7613(18)30005-0. doi: 10.1016/j.immuni.2018.01.005.
  294. Georgiev IS, Joyce MG, Chen RE, Leung K, McKee K, Druz A, Van Galen JG, Kanekiyo M, Tsybovsky Y, Yang ES, Yang Y, Acharya P, Pancera M, Thomas PV, Wanninger T, Yassine H, Baxa U, Doria-Rose N, Cheng C, Graham BS, Mascola JR, Kwong PD. Two-component ferritin nanoparticles for multimerization of diverse trimeric antigens. ACS Infectious Diseases 2018 Feb 16. doi: 10.1021/acsinfecdis.7b00192.
  295. Yassine HM, McTamney PM, Boyington JC, Ruckwardt TJ, Crank MC, Smatti MK, Ledgerwood JE, Graham BS. Use of hemagglutinin stem probes demonstrate prevalence of broadly reactive group 1 influenza antibodies in human sera. Science Reports 2018; Jun 5;8(1):8628. doi: 10.1038/s41598-018-26538-7.
  296. Ke Z, Dillard RS, Chirkova T, Leon F, Stobart CC, Hampton CM, Strauss JD, Rajan D, Rostad CA, Taylor JV, Yi H, Shah R, Jin M, Hartert TV, Peebles RS Jr, Graham BS, Moore ML, Anderson LJ, Wright ER. The morphology and assembly of respiratory syncytial virus revealed by cryo-electron tomography. Viruses 2018 Aug 20;10(8). pii: E446. doi: 10.3390/v10080446.
  297. Morabito KM, Ruckwardt TJ, Bar-Haim E, Nair D, Moin SM, Redwood AJ, Price DA, Graham BS. Memory inflation drives tissue-resident memory CD8+ T cell maintenance in the lung after intranasal vaccination with murine cytomegalovirus. Frontiers in Immunology 2018 Aug 14; 9:1861. doi: 10.3389/fimmu.2018.01861.
  298. Zheng QB, Zhu R, Xu LF, He MH, Yan XD, Liu DX, Yin ZC, Wu YT, Li YC, Yang LH, Hou WH, Li SX, Li ZH, Chen ZQ, Li ZH, Yu H, Gu Y, Zhang J, Baker TS, Zhou ZH, Graham BS (co-communicating), Cheng T, Li SW, Xia NS. Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization. Nature Microbiology 2018 Nov 5; doi: 10.1038/s41564-018-0275-7.
  299. Kirchdoerfer RN, Wang N, Pallesen J, Wrapp D, Turner HL, Cottrell CA, Corbett KS, Graham BS, McLellan JS, Ward AB. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci Rep. 2018 Oct 24;8(1):15701. doi: 10.1038/s41598-018-34171-7.
  300. Houser KV, Yamshchikov GV, Bellamy AR, May J, Enama ME, Sarwar U, Larkin B, Bailer RT, Koup R, Paskel M, Subbarao K, Anderson E, Bernstein DI, Creech B, Keyserling H, Spearman P, Wright PF, Graham BS, Ledgerwood JE; VRC 702 study team. DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial. PLoS ONE 2018 Nov 2; 13(11):e0206837. doi: 10.1371/journal.pone.0206837.
  301. Kleine-Weber H, Elzayat MT, Wang L, Graham BS, Müller MA, Drosten C, Pöhlmann S, Hoffmann M. Mutations in the spike protein of MERS-CoV transmitted in Korea increase resistance towards antibody-mediated neutralization. Journal of Virology 2018 Nov 7; pii: JVI.01381-18. doi: 10.1128/JVI.01381-18.
  302. Park S, Lee Y, Kwon YM, Lee YT, Kim KH, Ko EJ, Jung JH, Song M, Graham B, Prausnitz MR, Kang SM. Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge. PLoS ONE 2018 Oct 26; 3(10):e0205071. doi: 10.1371/journal.pone.0205071.
  303. Rosen O, Chan LL, Abiona O, Gough P, Wang L, Shi W, Zhang Y, Wang N, Kong WP, McLellan JS, Graham BS, Corbett KS. A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry. Journal of Virological Methods 2018 Nov 20; pii: S0166-0934(18)30318-5. doi: 10.1016/j.jviromet.2018.11.009.
  304. Yamamoto T, Masuta Y, Momota M, Kanekiyo M, Kanuma T, Takahama S, Moriishi E, Yasutomi Y, Saito T, Graham BS, Takahashi Y, Ishii KJ. A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection. International Immunology 2018 Dec 7; doi: 10.1093/intimm/dxy069.
  305. Gaudinski MR, Coates EE, Novik L, Widge A, Houser KV, Burch E, Holman LA, Gordon IJ, Chen GL, Carter C, Nason M, Sitar S, Yamshchikov G, Berkowitz N, Andrews C, Vazquez S, Laurencot C, Misasi J, Arnold F, Carlton K, Lawlor H, Gall J, Bailer RT, McDermott A, Capparelli E, Koup RA, Mascola JR, Graham BS, Sullivan NJ, Ledgerwood JE; VRC 608 Study team. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019 Jan 24. pii: S0140-6736(19)30036-4. doi: 10.1016/S0140-6736(19)30036-4.
  306. Çuburu N, Kim R, Guittard GC, Thompson CD, Hamm DE, Pang YY, Graham BS, Lowy DR, Schiller JT. A prime-pull-amplify vaccination strategy to maximize induction of circulating and genital-resident intraepithelial CD8+ memory T cells. Journal of Immunology 2019 Feb 15; 202(4):1250-1264. doi: 10.4049/jimmunol.1800219.
  307. Kanekiyo M, Joyce MG, Gillespie RA, Gallagher JR, Andrews SF, Yassine HM, Wheatley AK, Fisher BE, Ambrozak DR, Creanga A, Leung K, Yang ES, Boyoglu-Barnum S, Georgiev IS, Tsybovsky Y, Prabhakaran MS, Andersen H, Kong WP, Baxa U, Zephir KL, Ledgerwood JE, Koup RA, Kwong PD, Harris AK, McDermott AB, Mascola JR, Graham BS. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nature Immunology 2019 Mar; 20(3):362-372. doi: 10.1038/s41590-018-0305-x. Epub 2019 Feb 11.
  308. Corbett KS, Moin SM, Yassine HM, Cagigi A, Kanekiyo M, Boyoglu-Barnum S, Myers SI, Tsybovsky Y, Wheatley AK, Schramm CA, Gillespie RA, Shi W, Wang L, Zhang Y, Andrews SF, Joyce MG, Crank MC, Douek DC, McDermott AB, Mascola JR, Graham BS (co-communicating), Boyington JC. Design of nanoparticulate group 2 influenza virus hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages. MBio. 2019 Feb 26;10(1). pii: e02810-18. doi: 10.1128/mBio.02810-18.
  309. Al Kahlout RA, Nasrallah GK, Farag EA, Wang L, Lattwein E, ‎Müller MA, El Zowalaty ME, Graham BS, Althani AA, Yassine HM. Comparative serological study for the prevalence of anti-MERS coronavirus antibodies in high- and low-risk groups in Qatar. Journal of Immunology Research 2019; doi.org/10.1155/2019/1386740.
  310. Sesterhenn F, Galloux M, Vollers SS, Csepregi L, Yang C, Descamps D, Bonet J, Friedensohn S, Gainza P, Corthésy P, Chen M, Rosset S, Rameix-Welti MA, Éléouët JF, Reddy ST, Graham BS, Riffault S, Correia BE. Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen. PLoS Biology 2019 Feb 21;17(2):e3000164. doi: 10.1371/journal.pbio.3000164.
  311. Phung E, Chang LA, Morabito KM, Kanekiyo M, Chen M, Nair D, Kumar A, Chen GL, Ledgerwood JE, Graham BS, Ruckwardt TJ. Epitope-specific serological assays for RSV: Conformation matters. Vaccines (Basel). 2019 Feb 23;7(1). pii: E23. doi: 10.3390/vaccines7010023.
  312. Adney DR, Wang L, van Doremalen N, Shi W, Zhang Y, Kong WP, Miller MR, Bushmaker T, Scott D, de Wit E, Modjarrad K, Petrovsky N, Graham BS, Bowen RA, Munster VJ. Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas. Viruses 2019 Mar 2;11(3). pii: E212. doi: 10.3390/v11030212.
  313. Al Kahlout RA, Nasrallah GK, Farag EA, Wang L, Lattwein E, Müller MA, El Zowalaty ME, Al Romaihi HE, Graham BS, Al Thani AA, Yassine HM. Comparative serological study for the prevalence of anti-MERS coronavirus antibodies in high- and low-risk groups in Qatar. Journal of Immunology Research 2019 Feb 18; 2019:1386740. doi: 10.1155/2019/1386740.
  314. Schepp R, de Haan CAM, Wilkins D, Layman H, Graham BS, Esser M, Berbers G. Development and standardisation of a high throughput multiplex immunoassay for the simultaneous quantification of specific antibodies to five RSV proteins. mSphere 2019 Apr 24; 4(2). pii: e00236-19. doi: 10.1128/mSphere.00236-19.
  315. Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Proulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O'Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV397 Study Group. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV 2019 Apr 15. pii: S2352-3018(19)30053-0. doi: 10.1016/S2352-3018(19)30053-0.
  316. Lee Y, Ko EJ, Kim KH, Lee YT, Hwang HS, Kwon YM, Graham BS, Kang SM. A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus. Virology 2019 May 28; 534:1-13. doi: 10.1016/j.virol.2019.05.010.
  317. Jennewein MF, Goldfarb I, Dolatshahi S, Cosgrove C, Noelette FJ, Krykbaeva M, Das J, Sarkar A, Gorman MJ, Fischinger S, Boudreau CM, Brown J, Cooperrider JH, Aneja J, Suscovich TJ, Graham BS, Lauer GM, Goetghebuer T, Marchant A, Lauffenburger D, Kim AY, Riley LE, Alter G. Fc Glycan-Mediated Regulation of Placental Antibody Transfer. Cell 2019 Jun 11. pii: S0092-8674(19)30615-4. doi: 10.1016/j.cell.2019.05.044.
  318. Jagger BW, Dowd KA, Chen RE, Desai P, Foreman B, Burgomaster KE, Himansu S, Kong WP, Graham BS, Pierson TC, Diamond MS. Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice. Journal of Infectious Diseases 2019 Jul 1. pii: jiz338. doi: 10.1093/infdis/jiz338.
  319. Andrews SF, Chambers MJ, Schramm CA, Plyler J, Raab JE, Kanekiyo M, Gillespie RA, Ransier A, Darko S, Hu J, Chen X, Yassine HM, Boyington JC, Crank MC, Chen GL, Coates E, Mascola JR, Douek DC, Graham BS, Ledgerwood JE, McDermott AB. Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin. Immunity 2019 Jul 16; pii: S1074-7613(19)30294-8. doi: 10.1016/j.immuni.2019.06.024.
  320. Crank MC, Ruckwardt TJ, Chen M, Morabito KM, Phung E, Costner PJ, Holman LA, Hickman SP, Berkowitz NM, Gordon IJ, Yamshchikov GV, Gaudinski MR, Kumar A, Chang LA, Moin SM, Hill JP, DiPiazza AT, Schwartz RM, Kueltzo L, Cooper JW, Chen P, Stein JA, Carlton K, Gall JG, Nason MC, Kwong PD, Chen GL, Mascola JR, McLellan JS, Ledgerwood JE, Graham BS, and the VRC 317 Study Team. A proof-of-concept for structure-based vaccine design targeting RSV in humans. Science 2019 Aug 2; 365(6452):505-509. doi: 10.1126/science.aav9033. (Recommended by Faculty of 1000) (“Building a Better Vaccine Against Severe Respiratory Illness,” selected by the Clinical Research Forum as a finalist for Top 10 Clinical Research Achievement Awards)
  321. DiPiazza AT, Hill JP, Graham BS, Ruckwardt TJ. OMIP-061: 20-color flow cytometry panel for high-dimensional characterization of murine antigen-presenting cells. Cytometry A 2019 Aug 19. doi: 10.1002/cyto.a.23880.
  322. Gaudinski MR, Houser KV, Doria-Rose NA, Chen GL, Rothwell RSS, Berkowitz N, Costner P, Holman LA, Gordon IJ, Hendel CS, Kaltovich F, Conan-Cibotti M, Gomez Lorenzo M, Carter C, Sitar S, Carlton K, Gall J, Laurencot C, Lin BC, Bailer RT, McDermott AB, Ko SY, Pegu A, Kwon YD, Kwong PD, Namboodiri AM, Pandey JP, Schwartz R, Arnold F, Hu Z, Zhang L, Huang Y, Koup RA, Capparelli EV, Graham BS, Mascola JR, Ledgerwood JE; VRC 605 study team. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV 2019 Aug 28; pii: S2352-3018(19)30181-X. doi: 10.1016/S2352-3018(19)30181-X.
  323. Rudicell RS, Garinot M, Kanekiyo M, Kamp HD, Swanson K, Chou TH, Dai S, Bedel O, Simard D, Gillespie RA, Yang K, Reardon M, Avila LZ, Besev M, Dhal PK, Dharanipragada R, Zheng L, Duan X, Dinapoli J, Vogel TU, Kleanthous H, Mascola JR, Graham BS, Haensler J, Wei CJ, Nabel GJ. Comparison of adjuvants to optimize influenza neutralizing antibody responses. Vaccine. 2019 Sep 4; pii: S0264-410X(19)31094-1. doi: 10.1016/j.vaccine.2019.08.030.
  324. Carter C, Houser KV, Yamshchikov GV, Bellamy AR, May J, Enama ME, Sarwar U, Larkin B, Bailer RT, Koup R, Chen GL, Patel SM, Winokur P, Belshe R, Dekker CL, Graham BS, Ledgerwood JE; VRC 703 study team. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. PLoS ONE 2019 Sep 18;14(9):e0222178. doi: 10.1371/journal.pone.0222178.
  325. Wang N, Rosen O, Wang L, Turner HL, Stevens LJ, Corbett KS, Bowman CA, Pallesen J, Shi W, Zhang Y, Leung K, Kirchdoerfer RN, Becker MM, Denison MR, Chappell JD, Ward AB, Graham BS, McLellan JS. Structural definition of a neutralization-sensitive epitope on the MERS-CoV S1-NTD. Cell Reports 2019 Sep 24; 28(13):3395-3405.e6. doi: 10.1016/j.celrep.2019.08.052.
  326. Sangesland M, Ronsard L, Kazer SW, Bals J, Boyoglu-Barnum S, Yousif AS, Barnes R, Feldman J, Quirindongo-Crespo M, McTamney PM, Rohrer D, Lonberg N, Chackerian B, Graham BS, Kanekiyo M, Shalek AK, Lingwood D. Germline-encoded affinity for cognate antigen enables vaccine amplification of a human broadly neutralizing response against influenza virus. Immunity. 2019 Sep 20; pii: S1074-7613(19)30372-3. doi: 10.1016/j.immuni.2019.09.001.
  327. Neidich SD, Fong Y, Li SS, Geraghty DE, Williamson BD, Young WC, Goodman D, Seaton KE, Shen X, Sawant S, Zhang L, deCamp AC, Blette BS, Shao M, Yates NL, Feely F, Pyo CW, Ferrari G; HVTN 505 Team, Frank I, Karuna ST, Swann EM, Mascola JR, Graham BS, Hammer SM, Sobieszczyk ME, Corey L, Janes HE, McElrath MJ, Gottardo R, Gilbert PB, Tomaras GD. Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. Journal of Clinical Investigation 2019 Oct 7; pii: 126391. doi: 10.1172/JCI126391.
  328. Cunningham CK, McFarland EJ, Morrison RL, Capparelli EV, Safrit JT, Mofenson LM, Mathieson B, Valentine ME, Perlowski C, Smith B, Hazra R, Purdue L, Muresan P, Harding PA, Mbengeranwa T, Robinson LG, Wiznia A, Theron G, Lin B, Bailer RT, Mascola JR, Graham BS. IMPAACT P1112 team. Safety, tolerability, and pharmacokinetics of the broadly neutralizing HIV-1 monoclonal antibody VRC01 in HIV-exposed newborn infants. Journal of Infectious Diseases 2019 Nov 4; pii: jiz532. doi: 10.1093/infdis/jiz532.
  329. Kallas EG, Grunenberg NA, Yu C, Manso B, Pantaleo G, Casapia M, Baden LR, Valencia J, Sobieszczyk M, Van Tieu H, Allen M, Hural J, Graham BS, Kublin J, Gilbert PB, Corey L, Goepfert PA, McElrath MJ, Johnson RP, Huang Y, Frahm N. Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. Science Translational Medicine 2019 Nov 20; 11(519). pii: eaaw1673. doi: 10.1126/scitranslmed.aaw1673.
  330. Setliff I, Shiakolas AR, Pilewski KA, Murji AA, Mapengo RE, Janowska K, Richardson S, Oosthuysen C, Raju N, Ronsard L, Kanekiyo M, Qin JS, Kramer KJ, Greenplate AR, McDonnell WJ, Graham BS, Connors M, Lingwood D, Acharya P, Morris L, Georgiev IS. High-throughput mapping of B cell receptor sequences to antigen specificity. Cell 2019 Nov 26; pii: S0092-8674(19)31224-3. doi: 10.1016/j.cell.2019.11.003.
  331. Van Rompay KKA, Keesler RI, Ardeshir A, Watanabe J, Usachenko J, Singapuri A, Cruzen C, Bliss-Moreau E, Murphy AM, Yee JL, Webster H, Dennis M, Singh T, Heimsath H, Lemos D, Stuart J, Morabito KM, Foreman BM, Burgomaster KE, Noe AT, Dowd KA, Ball E, Woolard K, Presicce P, Kallapur SG, Permar SR, Foulds KE, Coffey LL, Pierson TC, Graham BS. DNA vaccination before conception protects Zika virus-exposed pregnant macaques against prolonged viremia and improves fetal outcomes. Science Translational Medicine 2019 Dec 18; 11(523). pii: eaay2736. doi: 10.1126/scitranslmed.aay2736.
  332. Joyce MG, Bao A, Chen M, Georgiev IS, Ou L, Bylund T, Druz A, Kong WP, Peng D, Rundlet EJ, Van Galen JG, Wang S, Yang Y, Zhang B, Chuang GY, McLellan JS, Graham BS, Mascola JR, Kwong PD. Crystal structure and immunogenicity of the DS-Cav1-stabilized fusion glycoprotein from respiratory syncytial virus subtype B. Pathogens and Immunity 2019 Dec 11; 4(2):294-323. doi: 10.20411/pai.v4i2.338.
  333. Boyoglu-Barnum S, Hutchinson GB, Boyington JC, Moin SM, Gillespie RA, Tsybovsky Y, Stephens T, Vaile JR, Lederhofer J, Corbett KS, Fisher BE, Yassine HM, Andrews SF, Crank MC, McDermott AB, Mascola JR, Graham BS (co-communicating), Kanekiyo M. Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses. Nature Communications 2020 Feb 7; 11(1):791. doi: 10.1038/s41467-020-14579-4.
  334. Liu X, Liang B, Liu X, Amaro-Carambot E, Surman S, Kwong PD, Graham BS, Collins PL, Munir S. Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates. PLoS One 2020 Feb 11; 15(2):e0228572. doi: 10.1371/journal.pone.0228572.
  335. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020 Feb 19:eabb2507. doi: 10.1126/science.abb2507.
  336. Clemens EA, Angeletti D, Holbrook BC, Kanekiyo M, Jorgensen MJ, Graham BS, Yewdell JW, Alexander-Miller MA. Influenza infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem. Journal of Clinical Investigation Insight. 2020 Feb 20:135449. doi: 10.1172/jci.insight.135449.
  337. Chen GL, Coates EE, Plummer SH, Carter CA, Berkowitz N, Conan-Cibotti M, Cox JH, Beck A, O'Callahan M, Andrews C, Gordon IJ, Larkin B, Lampley R, Kaltovich F, Gall J, Carlton K, Mendy J, Haney D, May J, Bray A, Bailer RT, Dowd KA, Brockett B, Gordon D, Koup RA, Schwartz R, Mascola JR, Graham BS, Pierson TC, Donastorg Y, Rosario N, Pape JW, Hoen B, Cabié A, Diaz C, Ledgerwood JE; VRC 704 Study Team. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial. JAMA. 2020 Apr 14;323(14):1369-1377. doi: 10.1001/jama.2020.2477.
  338. Freeman B, Lester S, Mills L, Rasheed MAU, Moye S, Abiona O, Hutchinson GB, Morales-Betoulle M, Krapinunaya I, Gibbons A, Chiang CF, Cannon D, Klena J, Johnson JA, Owen SM, Graham BS, Corbett KS, Thornburg NJ. Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance. bioRxiv [Preprint]. 2020 Apr 25; 2020.04.24.057323. doi: 10.1101/2020.04.24.057323.
  339. Choi JH, Woo HM, Lee TY, Lee SY, Shim SM, Park WJ, Yang JS, Kim JA, Yun MR, Kim DW, Kim SS, Zhang Y, Shi W, Wang L, Graham BS, Mascola JR, Wang N, McLellan JS, Lee JY, Lee H. Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus. PLoS One. 2020 May 8;15(5):e0232757. doi: 10.1371/journal.pone.0232757.
  340. Buchwald AG, Graham BS, Traore A, Haidara FC, Chen M, Morabito K, Lin BC, Sow SO, Levine MM, Pasetti MF, Tapia MD. Respiratory syncytial virus (RSV) neutralizing antibodies at birth predict protection from RSV illness in infants in the first 3 months of life. Clinical Infectious Diseases 2021 Dec 6; 73(11):e4421-e4427. doi: 10.1093/cid/ciaa648.
  341. Maciejewski S, Ruckwardt TJ, Morabito KM, Foreman BM, Burgomaster KE, Gordon DN, Pelc RS, DeMaso CR, Ko SY, Fisher BE, Yang ES, Nair D, Foulds KE, Todd JP, Wang LS, Kong WP, Roy V, Aleshnick M, Speer SD, Bourne N, Barrett AD, Nason MC, Roederer M, Gaudinski MR, Chen GL, Dowd KA, Ledgerwood JE, Alter G, Mascola JR, Graham BS, Pierson TC. Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Science Translational Medicine 2020 Jun 10; 12(547):eaaw9066. doi: 10.1126/scitranslmed.aaw9066.
  342. Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, Roose K, van Schie L; VIB-CMB COVID-19 Response Team, Hoffmann M, Pöhlmann S, Graham BS, Callewaert N, Schepens B, Saelens X, McLellan JS. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell. 2020 Jun 11;181(6):1436-1441. doi: 10.1016/j.cell.2020.05.047. Erratum for: Cell. 2020 May 28;181(5):1004-1015.e15.
  343. Wec AZ, Wrapp D, Herbert AS, Maurer DP, Haslwanter D, Sakharkar M, Jangra RK, Dieterle ME, Lilov A, Huang D, Tse LV, Johnson NV, Hsieh CL, Wang N, Nett JH, Champney E, Burnina I, Brown M, Lin S, Sinclair M, Johnson C, Pudi S, Bortz R 3rd, Wirchnianski AS, Laudermilch E, Florez C, Fels JM, O'Brien CM, Graham BS, Nemazee D, Burton DR, Baric RS, Voss JE, Chandran K, Dye JM, McLellan JS, Walker LM. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 2020 Jun 15; eabc7424. doi: 10.1126/science.abc7424.
  344. Loomis RJ, Stewart-Jones GBE, Tsybovsky Y, Caringal RT, Morabito KM, McLellan JS, Chamberlain AL, Nugent ST, Hutchinson GB, Kueltzo LA, Mascola JR, Graham BS. Structure-based design of Nipah virus vaccines: A generalizable approach to paramyxovirus immunogen development. Frontiers in Immunology 2020 Jun 11; 11:842. doi: 10.3389/fimmu.2020.00842.
  345. Hallowell BD, Carlson CM, Jacobs JR, Pomeroy M, Steinberg J, Tenforde M, McDonald E, Foster L, Feldstein LR, Rolfes MA, Haynes A, Abedi GR, Odongo GS, Saruwatari K, Rider EC, Douville G, Bhakta N, Maniatis P, Lindstrom S, Thornburg NJ, Lu X, Whitaker BL, Kamili S, Sakthivel SK, Wang L, Malapati L, Murray JR, Lynch B, Cetron M, Brown C, Roohi S, Rotz L, Borntrager D, Ishii K, Moser K, Rasheed M, Freeman B, Lester S, Corbett KS, Abiona OM, Hutchinson GB, Graham BS, Pesik N, Mahon B, Braden C, Behravesh CB, Stewart R, Knight N, Hall AJ, Killerby ME. Severe Acute Respiratory Syndrome coronavirus 2 prevalence, seroprevalence, and exposure among evacuees from Wuhan, China, 2020. Emerging Infectious Diseases 2020 Jul 3; 26(9). doi: 10.3201/eid2609.201590.
  346. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA 2nd, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS (co-senior author), Beigel JH; mRNA-1273 Study Group. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. New England Journal of Medicine 2020 Jul 14; NEJMoa2022483. doi: 10.1056/NEJMoa2022483.
  347. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O'Connell S, Bock KW, Minai M, Nagata BM, Andersen H, Martinez DR, Noe AT, Douek N, Donaldson MM, Nji NN, Alvarado GS, Edwards DK, Flebbe DR, Lamb E, Doria-Rose NA, Lin BC, Louder MK, O'Dell S, Schmidt SD, Phung E, Chang LA, Yap C, Todd JM, Pessaint L, Van Ry A, Browne S, Greenhouse J, Putman-Taylor T, Strasbaugh A, Campbell TA, Cook A, Dodson A, Steingrebe K, Shi W, Zhang Y, Abiona OM, Wang L, Pegu A, Yang ES, Leung K, Zhou T, Teng IT, Widge A, Gordon I, Novik L, Gillespie RA, Loomis RJ, Moliva JI, Stewart-Jones G, Himansu S, Kong WP, Nason MC, Morabito KM, Ruckwardt TJ, Ledgerwood JE, Gaudinski MR, Kwong PD, Mascola JR, Carfi A, Lewis MG, Baric RS, McDermott A, Moore IN, Sullivan NJ, Roederer M, Seder RA, Graham BS. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. New England Journal Medicine 2020 Jul 28; doi: 10.1056/NEJMoa2024671.
  348. Ueda G, Antanasijevic A, Fallas JA, Sheffler W, Copps J, Ellis D, Hutchinson GB, Moyer A, Yasmeen A, Tsybovsky Y, Park YJ, Bick MJ, Sankaran B, Gillespie RA, Brouwer PJ, Zwart PH, Veesler D, Kanekiyo M, Graham BS, Sanders RW, Moore JP, Klasse PJ, Ward AB, King NP, Baker D. Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. Elife 2020 Aug 4; 9:e57659. doi: 10.7554/eLife.57659.
  349. Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, Dinnon KH, Elbashir SM, Shaw CA, Woods A, Fritch EJ, Martinez DR, Bock KW, Minai M, Nagata BM, Hutchinson GB, Wu K, Henry C, Bahi K, Garcia-Dominguez D, Ma L, Renzi I, Kong WP, Schmidt SD, Wang L, Zhang Y, Phung E, Chang LA, Loomis RJ, Altaras NE, Narayanan E, Metkar M, Presnyak V, Liu C, Louder MK, Shi W, Leung K, Yang ES, West A, Gully KL, Stevens LJ, Wang N, Wrapp D, Doria-Rose NA, Stewart-Jones G, Bennett H, Alvarado GS, Nason MC, Ruckwardt TJ, McLellan JS, Denison MR, Chappell JD, Moore IN, Morabito KM, Mascola JR, Baric RS, Carfi A, Graham BS. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 2020 Aug 5; doi: 10.1038/s41586-020-2622-0.
  350. Luisi K, Morabito KM, Burgomaster KE, Sharma M, Kong WP, Foreman BM, Patel S, Fisher B, Aleshnick MA, Laliberte J, Wallace M, Ruckwardt TJ, Gordon DN, Linton C, Ruggiero N, Cohen JL, Johnson R, Aggarwal K, Ko SY, Yang ES, Pelc RS, Dowd KA, O'Hagan D, Ulmer J, Mossman S, Sambor A, Lepine E, Mascola JR, Pierson TC, Graham BS (co-communicating), Yu D. Development of a potent Zika virus vaccine using self-amplifying messenger RNA. Science Advances 2020 Aug 7; 6(32):eaba5068. doi: 10.1126/sciadv.aba5068.
  351. Li J, Nikanjam M, Cunningham CK, McFarland EJ, Coates EE, Houser KV, Lin BC, McDermott AB, Flach B, Gama L, Koup RA, Graham BS, Mascola JR, Ledgerwood JE, Capparelli EV. Model informed development of VRC01 in newborn infants using a population pharmacokinetics approach. Clinical Pharmacology Therapy 2020 Aug 31; doi: 10.1002/cpt.2026.
  352. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Corbett KS, Swanson PA 2nd, Padilla M, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Martinez DR, Baric R, Buchanan W, Luke CJ, Phadke VK, Rostad CA, Ledgerwood JE, Graham BS (co-senior author), Beigel JH; mRNA-1273 Study Group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. New England Journal of Medicine 2020 Sep 29; doi: 10.1056/NEJMoa2028436.
  353. Zhou T, Teng IT, Olia AS, Cerutti G, Gorman J, Nazzari A, Shi W, Tsybovsky Y, Wang L, Wang S, Zhang B, Zhang Y, Katsamba PS, Petrova Y, Banach BB, Fahad AS, Liu L, Lopez Acevedo SN, Madan B, Oliveira de Souza M, Pan X, Wang P, Wolfe JR, Yin M, Ho DD, Phung E, DiPiazza A, Chang LA, Abiona OM, Corbett KS, DeKosky BJ, Graham BS, Mascola JR, Misasi J, Ruckwardt T, Sullivan NJ, Shapiro L, Kwong PD. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Reports 2020 Oct 12; 108322. doi: 10.1016/j.celrep.2020.108322.
  354. Zhang B, Chao CW, Tsybovsky Y, Abiona OM, Hutchinson GB, Moliva JI, Olia AS, Pegu A, Phung E, Stewart-Jones GBE, Verardi R, Wang L, Wang S, Werner A, Yang ES, Yap C, Zhou T, Mascola JR, Sullivan NJ, Graham BS, Corbett KS, Kwong PD. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. Scientific Reports 2020 Oct 23; 10(1):18149. doi: 10.1038/s41598-020-74949-2.
  355. Clemens EA, Holbrook BC, Kanekiyo M, Yewdell JW, Graham BS, Alexander-Miller MA. An R848 conjugated influenza virus vaccine elicits robust IgG to hemagglutinin stem in a newborn nonhuman primate model. Journal of Infectious Diseases 2020 Nov 27; jiaa728. doi: 10.1093/infdis/jiaa728.
  356. Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Buchanan W, Luke CJ, Ledgerwood JE, Mascola JR, Graham BS (co-senior author), Beigel JH; mRNA-1273 Study Group. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. New England Journal of Medicine 2020 Dec 3; doi: 10.1056/NEJMc2032195.
  357. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Kehtan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine 2020 Dec 30; doi: 10.1056/NEJMoa2035389.
  358. Li D, Edwards RJ, Manne K, Martinez DR, Schäfer A, Alam SM, Wiehe K, Lu X, Parks R, Sutherland LL, Oguin TH, McDanal C, Perez LG, Mansouri K, Gobeil SMC, Janowska K, Stalls V, Kopp M, Cai F, Lee E, Foulger A, Hernandez GE, Sanzone A, Tilahun K, Jiang C, Tse LV, Bock KW, Minai M, Nagata BM, Cronin K, Gee-Lai V, Deyton M, Barr M, Von Holle T, Macintyre AN, Stover E, Feldman J, Hauser BM, Caradonna TM, Scobey TD, Moody MA, Cain DW, DeMarco CT, Denny TN, Woods CW, Petzold EW, Schmidt AG, Teng IT, Zhou T, Kwong PD, Mascola JR, Graham BS, Moore IN, Seder R, Andersen H, Lewis MG, Montefiori DC, Sempowski GD, Baric RS, Acharya P, Haynes BF, Saunders KO. The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. bioRxiv [Preprint]. 2021 Jan 2:2020.12.31.424729. doi: 10.1101/2020.12.31.424729.
  359. Yang Y, Shi W, Abiona OM, Nazzari A, Olia AS, Ou L, Phung E, Stephens T, Tsybovsky Y, Verardi R, Wang S, Werner A, Yap C, Ambrozak D, Bylund T, Liu T, Nguyen R, Wang L, Zhang B, Zhou T, Chuang GY, Graham BS, Mascola JR, Corbett KS, Kwong PD. Newcastle disease virus-like particles displaying prefusion-stabilized SARS-CoV-2 spikes elicit potent neutralizing responses. Vaccines (Basel). 2021 Jan 21; 9(2):73. doi: 10.3390/vaccines9020073.
  360. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y, Ho DD. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature 2021 Mar 8; doi: 10.1038/s41586-021-03398-2.
  361. Darricarrère N, Qiu Y, Kanekiyo M, Creanga A, Gillespie RA, Moin SM, Saleh J, Sancho J, Chou TH, Zhou Y, Zhang R, Dai S, Moody A, Saunders KO, Crank MC, Mascola JR, Graham BS, Wei CJ, Nabel GJ. Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. Science Translational Medicine 2021 Mar 3; 13(583):eabe5449. doi: 10.1126/scitranslmed.abe5449.
  362. Hicks J, Klumpp-Thomas C, Kalish H, Shunmugavel A, Mehalko J, Denson JP, Snead KR, Drew M, Corbett KS, Graham BS, Hall MD, Memoli MJ, Esposito D, Sadtler K. Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal betacoronaviruses. Journal of Clinical Immunology 2021 Mar 16; doi: 10.1007/s10875-021-00997-6.
  363. Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, Colpitts T, Bennett H, Boyoglu-Barnum S, Shi W, Moliva JI, Sullivan NJ, Graham BS, Carfi A, Corbett KS, Seder RA, Edwards DK. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. New England Journal of Medicine 2021 Mar 17; doi: 10.1056/NEJMc2102179.
  364. Fahad AS, Timm MR, Madan B, Burgomaster KE, Dowd KA, Normandin E, Gutiérrez-González MF, Pennington JM, De Souza MO, Henry AR, Laboune F, Wang L, Ambrozak DR, Gordon IJ, Douek DC, Ledgerwood JE, Graham BS, Castilho LR, Pierson TC, Mascola JR, DeKosky BJ. Functional profiling of antibody immune repertoires in convalescent Zika virus disease patients. Frontiers in Immunology 2021 Feb 24; 12:615102. doi: 10.3389/fimmu.2021.615102.
  365. Creanga A, Gillespie RA, Fisher BE, Andrews SF, Lederhofer J, Yap C, Hatch L, Stephens T, Tsybovsky Y, Crank MC, Ledgerwood JE, McDermott AB, Mascola JR, Graham BS (co-communicating), Kanekiyo M. A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies. Nature Communications 2021 Mar 19; 12(1):1722. doi: 10.1038/s41467-021-21954-2.
  366. Boyoglu-Barnum S, Ellis D, Gillespie RA, Hutchinson GB, Park YJ, Moin SM, Acton OJ, Ravichandran R, Murphy M, Pettie D, Matheson N, Carter L, Creanga A, Watson MJ, Kephart S, Ataca S, Vaile JR, Ueda G, Crank MC, Stewart L, Lee KK, Guttman M, Baker D, Mascola JR, Veesler D, Graham BS (co-communicating), King NP, Kanekiyo M. Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature 2021 Mar 24; doi: 10.1038/s41586-021-03365-x.
  367. Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, Wiethoff CM, Blackbourne JL, Heinz BA, Foster D, Higgs RE, Balasubramaniam D, Wang L, Zhang Y, Yang ES, Bidshahri R, Kraft L, Hwang Y, Žentelis S, Jepson KR, Goya R, Smith MA, Collins DW, Hinshaw SJ, Tycho SA, Pellacani D, Xiang P, Muthuraman K, Sobhanifar S, Piper MH, Triana FJ, Hendle J, Pustilnik A, Adams AC, Berens SJ, Baric RS, Martinez DR, Cross RW, Geisbert TW, Borisevich V, Abiona O, Belli HM, de Vries M, Mohamed A, Dittmann M, Samanovic MI, Mulligan MJ, Goldsmith JA, Hsieh CL, Johnson NV, Wrapp D, McLellan JS, Barnhart BC, Graham BS, Mascola JR, Hansen CL, Falconer E. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in non-human primates. Science Translational Medicine 2021 Apr 5; eabf1906. doi: 10.1126/scitranslmed.abf1906.
  368. Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, Ledgerwood JE, Mascola JR, Graham BS, Lin BC, O'Dell S, Schmidt SD, Widge AT, Edara VV, Anderson EJ, Lai L, Floyd K, Rouphael NG, Zarnitsyna V, Roberts PC, Makhene M, Buchanan W, Luke CJ, Beigel JH, Jackson LA, Neuzil KM, Bennett H, Leav B, Albert J, Kunwar P; mRNA-1273 Study Group. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19. New England Journal of Medicine 2021 Apr 6; doi: 10.1056/NEJMc2103916.
  369. Mukhamedova M, Wrapp D, Shen CH, Gilman MSA, Ruckwardt TJ, Schramm CA, Ault L, Chang L, Derrien-Colemyn A, Lucas SAM, Ransier A, Darko S, Phung E, Wang L, Zhang Y, Rush SA, Madan B, Stewart-Jones GBE, Costner PJ, Holman LA, Hickman SP, Berkowitz NM, Doria-Rose NA, Morabito KM, DeKosky BJ, Gaudinski MR, Chen GL, Crank MC, Misasi J, Sullivan NJ, Douek DC, Kwong PD, Graham BS, McLellan JS, Mascola JR. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. Immunity. 2021 Apr 2; S1074-7613(21)00116-3. doi: 10.1016/j.immuni.2021.03.004.
  370. Ruckwardt TJ, Morabito KM, Phung E, Crank MC, Costner PJ, Holman LA, Chang LA, Hickman SP, Berkowitz NM, Gordon IJ, Yamshchikov GV, Gaudinski MR, Lin B, Bailer R, Chen M, Ortega-Villa AM, Nguyen T, Kumar A, Schwartz RM, Kueltzo LA, Stein JA, Carlton K, Gall JG, Nason MC, Mascola JR, Chen G, Graham BS; VRC 317 study team. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respiratory Medicine 2021 Apr 14; S2213-2600(21)00098-9. doi: 10.1016/S2213-2600(21)00098-9.
  371. Burgomaster KE, Foreman BM, Aleshnick MA, Larman BC, Gordon DN, Maciejewski S, Morabito KM, Ledgerwood JE, Gaudinski MR, Chen GL, Mascola JR, Debbink K, Dowd KA, Graham BS, Pierson TC. Limited flavivirus cross-reactive antibody responses elicited by a ZIKV DNA vaccine candidate in humans. Journal of Infectious Disease 2021 May 7; jiab185. doi: 10.1093/infdis/jiab185.
  372. Westendorf K, Žentelis S, Foster D, Vaillancourt P, Wiggin M, Lovett E, Hendle J, Pustilnik A, Sauder JM, Kraft L, Hwang Y, Siegel RW, Chen J, Heinz BA, Higgs RE, Kalleward N, Jepson K, Goya R, Smith MA, Collins DW, Pellacani D, Xiang P, de Puyraimond V, Ricicova M, Devorkin L, Pritchard C, O'Neill A, Cohen C, Dye J, Huie KI, Badger CV, Kobasa D, Audet J, Freitas JJ, Hassanali S, Hughes I, Munoz L, Palma HC, Ramamurthy B, Cross RW, Geisbert TW, Borisevich V, Lanz I, Anderson L, Sipahimalani P, Corbett KS, Wang L, Yang ES, Zhang Y, Shi W, Graham BS, Mascola JR, Fernandez TL, Hansen CL, Falconer E, Jones BE, Barnhart BC. LY-CoV1404 potently neutralizes SARS-CoV-2 variants. bioRxiv [Preprint]. 2021 May 4; 2021.04.30.442182. doi: 10.1101/2021.04.30.442182.
  373. McFarland EJ, Cunningham CK, Muresan P, Capparelli EV, Perlowski C, Morgan P, Smith B, Hazra R, Purdue L, Harding PA, Theron G, Mujuru H, Agwu A, Purswani M, Rathore MH, Flach B, Taylor A, Lin BC, McDermott AB, Mascola JR, Graham BS; IMPAACT P1112 team. Safety, tolerability, and pharmacokinetics of a long-acting broadly neutralizing HIV-1 monoclonal antibody VRC01LS in HIV-1-exposed newborn infants. Journal of Infectious Diseases 2021 May 2; jiab229. doi: 10.1093/infdis/jiab229.
  374. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, Flowers MW, Hussaini L, Ciric CR, Bechnack S, Stephens K, Mokhtari EB, Mudvari P, Creanga A, Pegu A, Derrien-Colemyn A, Henry AR, Gagne M, Graham BS, Wrammert J, Douek DC, Boritz E, Pinsky BA, Suthar MS. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv [Preprint]. 2021 May 10; 2021.05.09.443299. doi: 10.1101/2021.05.09.443299.
  375. Salimi V, Viegas M, Trento A, Agoti CN, Anderson LJ, Avadhanula V, Bahl J, Bont L, Brister JR, Cane PA, Galiano M, Graham BS, Hatcher EL, Hellferscee O, Henke DM, Hirve S, Jackson S, Keyaerts E, Kragten-Tabatabaie L, Lindstrom S, Nauwelaers I, Nokes DJ, Openshaw PJ, Peret TC, Piedra PA, Ramaekers K, Rector A, Trovão NS, von Gottberg A, Zambon M, Zhang W, Williams TC, Barr IG, Buchholz UJ. Proposal for human respiratory syncytial virus nomenclature below the species level. Emerging Infectious Diseases 2021 Jun; 27(6):1-9. doi: 10.3201/eid2706.204608.
  376. Shiakolas AR, Kramer KJ, Wrapp D, Richardson SI, Schäfer A, Wall S, Wang N, Janowska K, Pilewski KA, Venkat R, Parks R, Manamela NP, Raju N, Fechter EF, Holt CM, Suryadevara N, Chen RE, Martinez DR, Nargi RS, Sutton RE, Ledgerwood JE, Graham BS, Diamond MS, Haynes BF, Acharya P, Carnahan RH, Crowe JE Jr, Baric RS, Morris L, McLellan JS, Georgiev IS. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Reports Medicine 2021 May 21; 100313. doi: 10.1016/j.xcrm.2021.100313.
  377. Taleb SA, Al-Ansari K, Nasrallah GK, Elrayess MA, Al-Thani AA, Derrien-Colemyn A, Ruckwardt TJ, Graham BS, Yassine HM. Level of maternal respiratory syncytial virus (RSV) F antibodies in hospitalized children and correlates of protection. International Journal of Infectious Diseases 2021 Jun 9; S1201-9712(21)00504-X. doi: 10.1016/j.ijid.2021.06.015.
  378. Chuang GY, Shen CH, Cheung CS, Gorman J, Creanga A, Joyce MG, Leung K, Rawi R, Wang L, Yang ES, Yang Y, Zhang B, Zhang Y, Kanekiyo M, Zhou T, DeKosky BJ, Graham BS, Mascola JR, Kwong PD. Sequence-signature optimization enables improved identification of human HV6-1-derived class antibodies that neutralize diverse influenza A viruses. Frontiers in Immunology 2021 May 31; 12:662909. doi: 10.3389/fimmu.2021.662909.
  379. Francica JR, Flynn BJ, Foulds KE, Noe AT, Werner AP, Moore IN, Gagne M, Johnston TS, Tucker C, Davis RL, Flach B, O'Connell S, Andrew SF, Lamb E, Flebbe DR, Nurmukhambetova ST, Donaldson MM, Todd JM, Zhu AL, Atyeo C, Fischinger S, Gorman MJ, Shin S, Edara VV, Floyd K, Lai L, Boyoglu-Barnum S, Van De Wetering R, Taylor A, McCarthy E, Lecouturier V, Ruiz S, Berry C, Tibbitts T, Andersen H, Cook A, Dodson A, Pessaint L, Van Ry A, Koutsoukos M, Gutzeit C, Teng IT, Zhou T, Li D, Haynes BF, Kwong PD, McDermott A, Lewis MG, Fu TM, Chicz R, van der Most R, Corbett KS, Suthar MS, Alter G, Roederer M, Sullivan NJ, Douek DC, Graham BS, Casimiro D, Seder RA. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Science Translational Medicine 2021 Jul 27; eabi4547. doi: 10.1126/scitranslmed.abi4547.
  380. Pegu A, O'Connell S, Schmidt SD, O'Dell S, Talana CA, Lai L, Albert J, Anderson E, Bennett H, Corbett KS, Flach B, Jackson L, Leav B, Ledgerwood JE, Luke CJ, Makowski M, Nason MC, Roberts PC, Roederer M, Rebolledo PA, Rostad CA, Rouphael NG, Shi W, Wang L, Widge AT, Yang ES; mRNA-1273 Study Group, Beigel JH, Graham BS, Mascola JR, Suthar MS, McDermott AB, Doria-Rose NA. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021 Aug 12:eabj4176. doi: 10.1126/science.abj4176.
  381. Corbett KS, Werner AP, Connell SO, Gagne M, Lai L, Moliva JI, Flynn B, Choi A, Koch M, Foulds KE, Andrew SF, Flebbe DR, Lamb E, Nurmukhambetova ST, Provost SJ, Bock KW, Minai M, Nagata BM, Ry AV, Flinchbaugh Z, Johnston TS, Mokhtari EB, Mudvari P, Henry AR, Laboune F, Chang B, Porto M, Wear J, Alvarado GS, Boyoglu-Barnum S, Todd JM, Bart B, Cook A, Dodson A, Pessaint L, Steingrebe K, Elbashir S, Sriparna M, Pekosz A, Andersen H, Wu K, Edwards DK, Kar S, Lewis MG, Boritz E, Moore IN, Carfi A, Suthar MS, McDermott A, Roederer M, Nason MC, Sullivan NJ, Douek DC, Graham BS (co-communicating), Seder RA. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nature Immunology 2021 Aug 20; doi: 10.1038/s41590-021-01021-0.
  382. Wang L, Zhou T, Zhang Y, Yang ES, Schramm CA, Shi W, Pegu A, Oloniniyi OK, Henry AR, Darko S, Narpala SR, Hatcher C, Martinez DR, Tsybovsky Y, Phung E, Abiona OM, Antia A, Cale EM, Chang LA, Choe M, Corbett KS, Davis RL, DiPiazza AT, Gordon IJ, Hait SH, Hermanus T, Kgagudi P, Laboune F, Leung K, Liu T, Mason RD, Nazzari AF, Novik L, O'Connell S, O'Dell S, Olia AS, Schmidt SD, Stephens T, Stringham CD, Talana CA, Teng IT, Wagner DA, Widge AT, Zhang B, Roederer M, Ledgerwood JE, Ruckwardt TJ, Gaudinski MR, Moore PL, Doria-Rose NA, Baric RS, Graham BS, McDermott AB, Douek DC, Kwong PD, Mascola JR, Sullivan NJ, Misasi J. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021 Aug 13;373(6556):eabh1766. doi: 10.1126/science.abh1766.
  383. Meyer M, Wang Y, Edwards D, Smith GR, Rubenstein AB, Ramanathan P, Mire CE, Pietzsch C, Chen X, Ge Y, Cheng WS, Henry C, Woods A, Ma L, Stewart-Jones GB, Bock KW, Minai M, Nagata BM, Periasamy S, Shi PY, Graham BS, Moore IN, Ramos I, Troyanskaya OG, Zaslavsky E, Carfi A, Sealfon SC, Bukreyev A. Attenuated activation of pulmonary immune cells in mRNA-1273 vaccinated hamsters after SARS-CoV-2 infection. Journal of Clinical Investigation 2021 Aug 27; 148036. doi: 10.1172/JCI148036.
  384. Corbett KS, Nason MC, Flach B, Gagne M, O'Connell S, Johnston TS, Shah SN, Edara VV, Floyd K, Lai L, McDanal C, Francica JR, Flynn B, Wu K, Choi A, Koch M, Abiona OM, Werner AP, Moliva JI, Andrew SF, Donaldson MM, Fintzi J, Flebbe DR, Lamb E, Noe AT, Nurmukhambetova ST, Provost SJ, Cook A, Dodson A, Faudree A, Greenhouse J, Kar S, Pessaint L, Porto M, Steingrebe K, Valentin D, Zouantcha S, Bock KW, Minai M, Nagata BM, van de Wetering R, Boyoglu-Barnum S, Leung K, Shi W, Yang ES, Zhang Y, Todd JM, Wang L, Alvarado GS, Andersen H, Foulds KE, Edwards DK, Mascola JR, Moore IN, Lewis MG, Carfi A, Montefiori D, Suthar MS, McDermott A, Roederer M, Sullivan NJ, Douek DC, Graham BS (co-communicating), Seder RA. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 2021 Sep 17; 373(6561):eabj0299. doi: 10.1126/science.abj0299.
  385. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schödel F, Tomassini JE, Zhou H, Miller J; COVE Study Group. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine 2021 Sep 22; doi: 10.1056/NEJMoa2113017.
  386. Corbett KS, Gagne M, Wagner DA, O' Connell S, Narpala SR, Flebbe DR, Andrew SF, Davis RL, Flynn B, Johnston TS, Stringham CD, Lai L, Valentin D, Van Ry A, Flinchbaugh Z, Werner AP, Moliva JI, Sriparna M, O'Dell S, Schmidt SD, Tucker C, Choi A, Koch M, Bock KW, Minai M, Nagata BM, Alvarado GS, Henry AR, Laboune F, Schramm CA, Zhang Y, Yang ES, Wang L, Choe M, Boyoglu-Barnum S, Wei S, Lamb E, Nurmukhambetova ST, Provost SJ, Donaldson MM, Marquez J, Todd JM, Cook A, Dodson A, Pekosz A, Boritz E, Ploquin A, Doria-Rose N, Pessaint L, Andersen H, Foulds KE, Misasi J, Wu K, Carfi A, Nason MC, Mascola J, Moore IN, Edwards DK, Lewis MG, Suthar MS, Roederer M, McDermott A, Douek DC, Sullivan NJ, Graham BS, Seder RA. Protection against SARS-CoV-2 beta variant in mRNA-1273 vaccine-boosted nonhuman primates. Science. 2021 Oct 21; eabl8912. doi: 10.1126/science.abl8912.
  387. Hsieh CL, Werner AP, Leist SR, Stevens LJ, Falconer E, Goldsmith JA, Chou CW, Abiona OM, West A, Westendorf K, Muthuraman K, Fritch EJ, Dinnon KH 3rd, Schäfer A, Denison MR, Chappell JD, Baric RS, Graham BS, Corbett KS, McLellan JS. Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Reports 2021 Oct 16; 109929. doi: 10.1016/j.celrep.2021.109929.
  388. Martinez DR, Schäfer A, Gobeil S, Li D, De la Cruz G, Parks R, Lu X, Barr M, Stalls V, Janowska K, Beaudoin E, Manne K, Mansouri K, Edwards RJ, Cronin K, Yount B, Anasti K, Montgomery SA, Tang J, Golding H, Shen S, Zhou T, Kwong PD, Graham BS, Mascola JR, Montefiori DC, Alam SM, Sempowski GD, Khurana S, Wiehe K, Saunders KO, Acharya P, Haynes BF, Baric RS. A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Science Translational Medicine 2021 Nov 2; eabj7125. doi: 10.1126/scitranslmed.abj7125.
  389. Wu K, Choi A, Koch M, Elbashir S, Ma L, Lee D, Woods A, Henry C, Palandjian C, Hill A, Jani H, Quinones J, Nunna N, O'Connell S, McDermott AB, Falcone S, Narayanan E, Colpitts T, Bennett H, Corbett KS, Seder R, Graham BS, Stewart-Jones GBE, Carfi A, Edwards DK. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Vaccine 2021 Nov 8; S0264-410X(21)01435-3. doi: 10.1016/j.vaccine.2021.11.001.
  390. Gagne M, Corbett KS, Flynn BJ, Foulds KE, Wagner DA, Andrew SF, Todd JM, Honeycutt CC, McCormick L, Nurmukhambetova ST, Davis-Gardner ME, Pessaint L, Bock KW, Nagata BM, Minai M, Werner AP, Moliva JI, Tucker C, Lorang CG, Zhao B, McCarthy E, Cook A, Dodson A, Teng IT, Mudvari P, Roberts-Torres J, Laboune F, Wang L, Goode A, Kar S, Boyoglu-Barnum S, Yang ES, Shi W, Ploquin A, Doria-Rose N, Carfi A, Mascola JR, Boritz EA, Edwards DK, Andersen H, Lewis MG, Suthar MS, Graham BS, Roederer M, Moore IN, Nason MC, Sullivan NJ, Douek DC, Seder RA. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell 2021 Dec 3; S0092-8674(21)01405-7. doi: 10.1016/j.cell.2021.12.002.
  391. Loomis RJ, DiPiazza AT, Falcone S, Ruckwardt TJ, Morabito KM, Abiona OM, Chang LA, Caringal RT, Presnyak V, Narayanan E, Tsybovsky Y, Nair D, Hutchinson GB, Stewart-Jones GBE, Kueltzo LA, Himansu S, Mascola JR, Carfi A, Graham BS. Chimeric fusion (F) and attachment (G) glycoprotein antigen delivery by mRNA as a candidate Nipah vaccine. Frontiers in Immunology 2021 Dec 8; 12:772864. doi: 10.3389/fimmu.2021.772864.
  392. Houser KV, Chen GL, Carter C, Crank MC, Nguyen TA, Burgos Florez MC, Berkowitz NM, Mendoza F, Hendel CS, Gordon IJ, Coates EE, Vazquez S, Stein J, Case CL, Lawlor H, Carlton K, Gaudinski MR, Strom L, Hofstetter AR, Liang CJ, Narpala S, Hatcher C, Gillespie RA, Creanga A, Kanekiyo M, Raab JE, Andrews SF, Zhang Y, Yang ES, Wang L, Leung K, Kong WP, Freyn AW, Nachbagauer R, Palese P, Bailer RT, McDermott AB, Koup RA, Gall JG, Arnold F, Mascola JR, Graham BS, Ledgerwood JE; VRC 316 Study Team. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nature Medicine 2022 Feb 3; doi: 10.1038/s41591-021-01660-8.
  393. Andrews SF, Raab JE, Gorman J, Gillespie RA, Cheung CSF, Rawi R, Cominsky LY, Boyington JC, Creanga A, Shen CH, Harris DR, Olia AS, Nazzari AF, Zhou T, Houser KV, Chen GL, Mascola JR, Graham BS, Kanekiyo M, Ledgerwood JE, Kwong PD, McDermott AB. A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. Nature Medicine 2022 Feb 3; doi: 10.1038/s41591-021-01636-8.
  394. Uppalapati L, Roitburd-Berman A, Weiss-Ottolenghi Y, Graham BS, Dimitrov DS, Ying T, Failayev H, Tsfadia Y, Gershoni JM. Functional reconstitution of the MERS CoV receptor binding motif. Molecular Immunology 2022 Mar 4; 145:3-16. doi:10.1016/j.molimm.2022.03.006.
  395. Zhou T, Wang L, Misasi J, Pegu A, Zhang Y, Harris DR, Olia AS, Talana CA, Yang ES, Chen M, Choe M, Shi W, Teng IT, Creanga A, Jenkins C, Leung K, Liu T, Stancofski ED, Stephens T, Zhang B, Tsybovsky Y, Graham BS, Mascola JR, Sullivan NJ, Kwong PD. Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. Science 2022 Mar 24; eabn8897. doi: 10.1126/science.abn8897.
  396. Ellis D, Lederhofer J, Acton OJ, Tsybovsky Y, Kephart S, Yap C, Gillespie RA, Creanga A, Olshefsky A, Stephens T, Pettie D, Murphy M, Sydeman C, Ahlrichs M, Chan S, Borst AJ, Park YJ, Lee KK, Graham BS, Veesler D, King NP, Kanekiyo M. Structure-based design of stabilized recombinant influenza neuraminidase tetramers. Nature Communications 2022 Apr 5; 13(1):1825. doi: 10.1038/s41467-022-29416-z.
  397. Casazza JP, Cale EM, Narpala S, Yamshchikov GV, Coates EE, Hendel CS, Novik L, Holman LA, Widge AT, Apte P, Gordon I, Gaudinski MR, Conan-Cibotti M, Lin BC, Nason MC, Trofymenko O, Telscher S, Plummer SH, Wycuff D, Adams WC, Pandey JP, McDermott A, Roederer M, Sukienik AN, O'Dell S, Gall JG, Flach B, Terry TL, Choe M, Shi W, Chen X, Kaltovich F, Saunders KO, Stein JA, Doria-Rose NA, Schwartz RM, Balazs AB, Baltimore D, Nabel GJ, Koup RA, Graham BS, Ledgerwood JE, Mascola JR; VRC 603 Study Team. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nature Medicine 2022 Apr 11; doi: 10.1038/s41591-022-01762-x.
  398. Besteman SB, Phung E, Raeven HHM, Amatngalim GD, Rumpret M, Crabtree J, Schepp RM, Rodenburg LW, Siemonsma SG, Verleur N, van Slooten R, Duran K, van Haaften G, Beekman JM, Chang LA, Meyaard L, van der Bruggen T, Berbers GAM, Derksen N, Nierkens S, Morabito KM, Ruckwardt TJ, Kurt-Jones EA, Golenbock D, Graham BS, Bont LJ. Recurrent respiratory syncytial virus infection in a CD14 deficient patient. Journal of Infectious Diseases 2022 Apr 16; jiac114. doi: 10.1093/infdis/jiac114.
  399. Westendorf K, Žentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, Lovett E, van der Lee R, Hendle J, Pustilnik A, Sauder JM, Kraft L, Hwang Y, Siegel RW, Chen J, Heinz BA, Higgs RE, Kallewaard NL, Jepson K, Goya R, Smith MA, Collins DW, Pellacani D, Xiang P, de Puyraimond V, Ricicova M, Devorkin L, Pritchard C, O'Neill A, Dalal K, Panwar P, Dhupar H, Garces FA, Cohen CA, Dye JM, Huie KE, Badger CV, Kobasa D, Audet J, Freitas JJ, Hassanali S, Hughes I, Munoz L, Palma HC, Ramamurthy B, Cross RW, Geisbert TW, Menachery V, Lokugamage K, Borisevich V, Lanz I, Anderson L, Sipahimalani P, Corbett KS, Yang ES, Zhang Y, Shi W, Zhou T, Choe M, Misasi J, Kwong PD, Sullivan NJ, Graham BS, Fernandez TL, Hansen CL, Falconer E, Mascola JR, Jones BE, Barnhart BC. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Reports 2022 Apr 25; 110812. doi: 10.1016/j.celrep.2022.110812.
  400. Phung E, Chang LA, Mukhamedova M, Yang L, Nair D, Rush SA, Morabito KM, McLellan JS, Buchholz UJ, Mascola JR, Crank MC, Chen G, Graham BS, Ruckwardt TJ. Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. Science Translational Medicine 2022 Jun 22; 14(650):eabo5032. doi: 10.1126/scitranslmed.abo5032.
  401. Houser KV, Gaudinski MR, Happe M, Narpala S, Verardi R, Sarfo EK, Corrigan AR, Wu R, Rothwell RS, Novik L, Hendel CS, Gordon IJ, Berkowitz NM, Cartagena CT, Widge AT, Coates EE, Strom L, Hickman S, Conan-Cibotti M, Vazquez S, Trofymenko O, Plummer S, Stein J, Case CL, Nason M, Biju A, Parchment DK, Changela A, Cheng C, Duan H, Geng H, Teng IT, Zhou T, O'Connell S, Barry C, Carlton K, Gall JG, Flach B, Doria-Rose NA, Graham BS, Koup RA, McDermott AB, Mascola JR, Kwong PD, Ledgerwood JE; VRC 018 Study Team. Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. EClinicalMedicine 2022 Jun 1; 48:101477. doi: 10.1016/j.eclinm.2022.101477.

Invited Reviews, Book Chapters, Monographs, Commentaries, and Meeting Reports

  1. Graham BS. Detection of bacteremia and fungemia: Microscopic examination of peripheral blood smears. Infection Control 1984; 5:448-452.
  2. Graham BS, Schaffner W. Hospital-Acquired Pneumonia. In Current Therapy in Infectious Diseases - 2. Kass EH, Platt R, editors. B.C. Decker Inc., C.V. Mosby Co., St. Louis, 1986, pp 134-145.
  3. Boldt J, Graham BS, Ratner H. Pasteurella multocida Clinical Microbiology Newsletter 1984; 6:67-68.
  4. Graham BS, Schaffner W. The fascinating zoonoses. Internal Medicine for the Specialist 1987; 8(10):56-66.
  5. Graham BS, Schneiderman H. Physical diagnosis: Skin signs of systemic disease. Consultant 1989; 29(4):31-48. (Republished Consultant June 1996.)
  6. Graham BS, Karzon DT. Development of an AIDS vaccine: Biological and ethical challenges. Infectious Disease Clinics of North America 1990; 4(2):223-243.
  7. Graham BS. Determinants of pathology in RSV-infected mice. In Animal Models of Respiratory Syncytial Virus Infections. Proceedings of the Institute Merieux. Veyrier-du-Lac, France, 1990, pp 49-52.
  8. Anderson LJ, Ananaba G, Tsou C, Graham BS, Walsh EE. Respiratory syncytial virus infection of macrophages. In Animal Models of Respiratory Syncytial Virus Infections. Proceedings of the Institute Merieux. Veyrier-du-Lac, France, 1990, pp 63-72.
  9. Graham BS. Clinical trials of AIDS vaccines in seronegative volunteers: Vectors and combinations. AIDS Research and Human Retroviruses 1992; 8:1327-1328.
  10. Graham BS. Serologic responses to candidate AIDS vaccines. AIDS Research and Human Retroviruses 1994; 10:S145-S148 (Supplement 2).
  11. Keefer MC, Belshe R, Graham B, McElrath J, Clements ML, Sposto R, Fast P. Safety profile of HIV vaccination: first 1000 volunteers of AIDS vaccine evaluation group. AIDS Research and Human Retroviruses 1994; 10:S139-S140 (Supplement 2).
  12. Graham BS, Wright PF. Candidate AIDS Vaccines. New England Journal of Medicine 1995; 333:1331-1339.
  13. Graham BS. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. American Journal of Respiratory and Critical Care Medicine 1995; 152:S63-S66.
  14. Tang YW, Graham BS. Anti-IL-4 treatment during immunization increases Th1-like cytokine expression and CTL activity in lungs of mice after challenge with RSV. Vaccines 95: Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, 1995, pp.257-262.
  15. Graham BS, Sawyer LA, Walker MC, Fast PE, Hu SL. Interface between animal models and clinical phase I trials: Report of a workshop. AIDS Research and Human Retroviruses 1995; 11:1305-1306.
  16. Walker MC, Fast PE, Graham BS, Belshe RB, Dolin R. Conference on AIDS Vaccine Development - 1994. Summary of Phase I/II preventive vaccine trials. AIDS Research and Human Retroviruses 1995; 11:1279-1285.
  17. McElrath MJ, Schacker T, Graham BS. Primary HIV-1 Infection in an Update for Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Mandell GL, Bennett JE, Dolin R, editors. Churchill Livingstone, Inc., New York, NY. 4(4):1-19, 1996.
  18. Tang YW, Graham BS. Potential for directing appropriate responses to vaccines by cytokine manipulation. Clinical Immunotherapeutics 1996; 5:327-333.
  19. Neuzil KM, Graham BS. Cytokines and innate immunity in respiratory viral infection. Seminars in Virology 1996; 7:255-264.
  20. Barr FE, Graham BS. RSV Bronchiolitis, in UpToDate, a CD-ROM-based medical textbook. Rose BD, Weinberger SE, editors. Published on CD-ROM by UpToDate, Inc., Wellesley, MA, 1997. Windows, Vol. 5, No. 2. Now web-based and published as three separate reviews that are continuously updated, “RSV: Clinical features and diagnosis” (>78,000 views in 2016); “RSV: Treatment” (>67,800 views in 2016); and “RSV: Prevention” (>24,300 views in 2017) current version 14.2.
  21. Graham BS. Immunologic determinants of RSV-induced disease. Trends in Microbiology 1996; 4:290-293.
  22. Barg N, Graham BS, Gregg C, Gregory D. Staphylococcus aureus infections in Atlas of Infectious Diseases. VIII. External Manifestations of Systemic Diseases. Fekety R, editor, Mandell GL, editor-in-chief. Current Medicine, Philadelphia, PA, 1997.
  23. Graham BS, Bartlett JG. HIV and AIDS, Chapter 2 in Infectious Diseases MKSAP, second edition. Klempner MS, editor, Lorber B, associate editor. American College of Physicians, Philadelphia, PA. 1998, pages 74-130.
  24. Graham BS. Section on Respiratory Viruses for Selected Virus Infections, Chapter 3 in Infectious Diseases MKSAP, second edition. Klempner MS, editor, Lorber B, associate editor. American College of Physicians, Philadelphia, PA. 1998, pages 154-160.
  25. Graham BS, Karzon DT. AIDS Vaccine Development in Textbook of AIDS Medicine, Second Edition. Merigan TC, Bartlett JG, Bolognesi D, editors. Williams & Wilkins, Baltimore, MD, 1998, Chapter 42, pages 689-724.
  26. Graham BS. Science, medicine, and the future: Infection with HIV-1. British Medical Journal 1998; 317:1297-1301.
  27. Walsh EE, Graham BS. Respiratory Syncytial Viruses in Viral Infections of the Respiratory Tract for the Series Lung Biology in Health and Disease. Volume 27. Dolin R, Wright PF, editors. Marcel Dekker, Inc., New York, NY. 1999, Chapter 7, pages 161-203.
  28. Graham BS. Clinical Trials of HIV Vaccines in HIV Molecular Immunology Database Compendium. Korber BTM, Moore JP, Brander C, Walker BD, Haynes BF, Koup R, editors. Los Alamos National Laboratory: Theoretical Biology and Biophysics, Los Alamos, NM, 2000, pages I-20 – I-38. (internet access – http://hiv-web.lanl.gov/immunology)
  29. Peebles RS, Graham BS. Viruses, dendritic cells, and the lung. Respiratory Research 2001; 2:245-249.
  30. Graham BS. Clinical Trials of HIV Vaccines. Annual Review of Medicine 2002; 53:207-221.
  31. Graham BS, Rutigliano JA, Johnson TR. Respiratory syncytial virus immunobiology and pathogenesis. Virology 2002; 297:1-7.
  32. Peebles RS, Hashimoto K, Graham BS. The complex relationship between respiratory syncytial virus and allergy in lung disease. Viral Immunology 2003; 16: 5-34.
  33. Womack CA, Liu M, Graham BS. Challenges and Current Progress in the Development of HIV/AIDS Vaccines, in New Generation Vaccines. Third edition, Levine MM, Kaper JB, Rappuoli R, Liu M, Good M, editors. Marcel Dekker, Inc., New York, NY, 2003, pages 573-581.
  34. Johnson TR, Graham BS. The contribution of respiratory syncytial virus (RSV) G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary RSV infection. The Pediatric Infectious Disease Journal 2004; 23: S46-S57.
  35. Budge PJ, Graham BS. Inhibition of respiratory syncytial virus by RhoA-derived peptides: Implications for the development of improved antiviral agents against heparin-binding viruses. Journal of Antimicrobial Chemotherapy 2004; 54:299-302.
  36. Schmidt AC, Johnson TR, Openshaw PJM, Braciale TJ, Falsey AR, Anderson LJ, Wertz GW, Groothuis JR, Prince GA, Melero JA, Graham BS. Respiratory syncytial virus and other pneumoviruses: A review of the international symposium - RSV 2003. Virus Research 2004; 106:1–13.
  37. Graham BS, Mascola JR. Lessons from failure – Preparing for future HIV vaccine efficacy trials [Editorial]. Journal of Infectious Diseases 2005; 191:647-649.
  38. Peebles RS, Jr., Graham BS. Pathogenesis of respiratory syncytial virus in the murine model. Proceedings of the American Thoracic Society 2005; 2:110-115.
  39. Catanzaro AT, Graham BS. Rationale for Current HIV Vaccine Clinical Trials, in “Recent Advances in HIV Infection Research”. Gualberto Buela-Casal and María Paz Bermúdez, editors, University of Granada. Spain. 2006; Chapter 9: 261-291.
  40. Graham BS. New approaches to vaccine adjuvants: Inhibiting the inhibitor [Editorial]. PLoS Medicine 2006; 3:18-20.
  41. Parrino J, Graham BS. Smallpox vaccines: Past, present, and future. Journal of Allergy and Clinical Immunology 2006; 118:1320-1326.
  42. Graham BS, Crowe JE, Jr. Immunization Against Viral Diseases, in “Fields Virology”, Fifth edition, David M. Knipe and Peter M. Howley, editors. Lippincott Williams & Wilkins. Philadelphia, PA, 2007; Chapter 15: 487-538.
  43. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. Journal of Virology 2008; 82:2040-2055. Epub 2007 Oct 10.
  44. Martin JE, Graham BS. Vaccination Against Viral Diseases, in “Clinical Virology”, 3rd Edition, Richman DD, Hayden FG, Whitley RJ, editors. ASM Press. Herndon, VA, 2009; Chapter 15: pages 333-349.
  45. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Ebola virus immunity: Correlates of protection as a basis for vaccine approval by the Animal Rule. Nature Reviews Microbiology 2009; 7:393-400.
  46. Ledgerwood JE, Graham BS. DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases. Human Vaccines 2009; 5:623-626. 
  47. Graham BS, Ledgerwood JE, Nabel GJ. Vaccine development in the 21st century: Changing paradigms for elusive viruses. Clinical Pharmacology and Therapeutics 2009; 86:234-236.
  48. Graham BS, Nabel GJ. Challenges and Prospects for the Development of an HIV Vaccine, in New Generation Vaccines. Fourth edition, Levine MM, Dougan G, Good MF, Liu MA, Nabel GJ, Nataro JP, Rappuoli R, editors. Informa Healthcare, New York, NY, 2010, Chapter 55: pages 585-592.
  49. Graham BS. What does the report of the USMHRP Phase III study in Thailand mean for HIV and for vaccine developers?  Clinical and Experimental Immunology 2009; 158:257-259.
  50. Graham BS, Walker C. Meeting the Challenge of Vaccine Design to Control HIV and Other Difficult Viruses, in The Immune Response to Infection. Kaufmann SHE, Rouse BT, Sacks DL, editors. ASM Press, Washington, DC, 2011, Chapter 44: pages 559-570.
  51. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunological Reviews 2011; 239(1):149-166. doi: 10.1111/j.1600-065X.2010.00972.x.
  52. Koup RA, Graham BS, Douek DC. The quest for a T cell immune correlate of protection against HIV: A story of trials and errors. Nature Reviews Immunology 2011; 11:65-70. Epub 2010 Dec 17.
  53. Graham BS, Crowe JE, Jr. Tribute to David T. Karzon, MD and Robert M. Chanock, MD. Vaccine 2011; 29:3725–3727.
  54. Graham BS. Future opportunities for passive immunity against viral diseases [Editorial]. Journal of Infectious Diseases 2011; 204:1648-1650. Epub 2011 Oct 12.
  55. Rimoin AW, Graham BS. Whither monkeypox vaccination. Vaccine 2011; 29 Suppl 4: D60-64. Epub 2011 Dec 19.
  56. Graham BS, Crowe JE, Jr., Ledgerwood JE. Immunization Against Viral Diseases, in “Fields Virology”, Sixth edition, David M. Knipe and Peter M. Howley, editors. Lippincott Williams & Wilkins. Philadelphia, PA, 2013; Chapter 14: pages 374-413.
  57. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. Strategic priorities for RSV vaccine development. (for Decade of Vaccines Working Group) Vaccine 2013; Suppl 2 B209-215. doi: 10.1016/j.vaccine.2012.11.106.
  58. Graham BS. Advances in anti-viral vaccine development. Immunological Reviews 2013; 255(1):230-42. doi: 10.1111/imr.12098.
  59. Collins PL, Fearns R, Graham BS. RSV: Virology, Reverse Genetics, and Pathogenesis of Disease, in Challenges and Opportunities for Respiratory Syncytial Virus Vaccines, in the series, “Current Topics in Microbiology and Immunology”, Larry J. Anderson and Barney S. Graham, editors. Springer, Heidelberg, Germany, 2013, Volume 372, Chapter 1, pages 3-38. doi: 10.1007/978-3-642-38919-1_1.
  60. Graham BS, Anderson LJ. Challenges and Opportunities for Respiratory Syncytial Virus Vaccines, in Challenges and Opportunities for Respiratory Syncytial Virus Vaccines, in the series, “Current Topics in Microbiology and Immunology”, Larry J. Anderson and Barney S. Graham, editors. Springer, Heidelberg, Germany, 2013, Volume 372, Chapter 20, pages 391-404. doi: 10.1007/978-3-642-38919-1_20.
  61. Voronin Y, Mofenson LM, Cunningham CK, Fowler MG, Kaleebu P, McFarland EJ, Safrit JT, Graham BS, Snow W. HIV monoclonal antibodies: A new opportunity to further reduce mother-to-child HIV transmission. PLoS Medicine 2014; Apr 8;11(4):e1001616. doi: 10.1371/journal.pmed.1001616.
  62. Graham BS. Protecting the family to protect the child: Vaccination strategy guided by RSV transmission dynamics [commentary]. Journal of Infectious Diseases 2014; 209:1679-1681. doi: 10.1093/infdis/jiu075. Epub 2014 Feb 12.
  63. Graham BS, Ambrosino DM. History of passive antibody administration for prevention and treatment of infectious diseases. Current Opinion in HIV and AIDS 2015; 10(3):129-34. doi: 10.1097/COH.0000000000000154. Epub 2015 Mar 10.
  64. Graham BS, Modjarrad K, McLellan JS. Novel Antigens for RSV Vaccines. Current Opinion in Immunology 2015; 35:30-38. doi: 10.1016/j.coi.2015.04.005.
  65. Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS, WHO RSV Vaccine Consultation Expert Group. WHO consultation on RSV vaccine development report from a World Health Organization meeting held on 23-24 March 2015. Vaccine 2015 Jun 20. pii: S0264-410X(15)00767-7. doi: 10.1016/j.vaccine.2015.05.093.
  66. Giersing BK, Modjarrad K, Kaslow DC, Moorthy VS, WHO Product Development for Vaccines Advisory Committee. Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015. Vaccine. 2016 Jun 3;34(26):2865-2869. doi: 10.1016/j.vaccine.2016.02.078. Epub 2016 Mar 15.
  67. Ruckwardt TJ, Morabito KM, Graham BS. Determinants of early life immune responses to RSV infection. Current Opinion in Virology 2016 Feb;16:151-7. doi: 10.1016/j.coviro.2016.01.003. Epub 2016 Mar 15.
  68. DeZure A, Graham BS. Vaccines for Emerging Viral Diseases. The Vaccine Book, 2nd Barry R. Bloom and Paul-Henri Lambert, editors. Elsevier. 2016; Chapter 28, pages 543-560.
  69. Graham BS. Vaccines against respiratory syncytial virus: The time has finally come. Vaccine 2016 May 13. pii: S0264-410X(16)30257-2. doi: 10.1016/j.vaccine.2016.04.083.
  70. Roberts JN, Graham BS, Karron RA, Munoz FM, Falsey AR, Anderson LJ, Marshall V, Kim S, Beeler JA. Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop. Vaccine 2016 Sep 22; 34(41):4843-9. Epub 2016 Aug 23.
  71. Cibrelus L, Graham BS, Ramon-Pardo P, Repik P, Yactayo S. Chikungunya disease: Gaps and opportunities in public health and research in the Americas. Weekly Epidemiological Record of the WHO 2015; 90(42): 571-577.
  72. Graham BS, Repik PM, Yactayo S. Chikungunya disease in the Americas: Recommendations and conclusions. Journal of Infectious Diseases 2016 Dec 15;214 (suppl 5):S510-S513.
  73. DeZure AD, Berkowitz NM, Graham BS, Ledgerwood JE. Whole-Inactivated and virus-like particle vaccine strategies for chikungunya virus. Journal of Infectious Diseases 2016 Dec 15; 214 (suppl 5):S497-S499.
  74. Pierson TC, Graham BS. Zika virus immunity and vaccine development. Cell 2016 Oct 20; 167(3):625-631.
  75. Graham BS. Vaccine development for respiratory syncytial virus. Current Opinions in Virology 2017 May 16; 23:107-112. doi: 10.1016/j.coviro.2017.03.012.
  76. Andrews SF, Graham BS, Mascola JR, McDermott AB. Immunogenetic considerations underlying B cell biology in the development of a pan-subtype influenza A vaccine targeting the hemagglutinin stem, in Immune Memory and Vaccines: Great Debates, Cold Spring Harbor Perspectives in Biology 2017 Jun 29. pii: a029413. doi: 10.1101/cshperspect.a029413.
  77. Plotkin SA, Graham BS. Zika Virus, in “Plotkin's Vaccines”, Seventh edition, Stanley A. Plotkin, Walter A. Orenstein, Paul A. Offit, Kathryn M. Edwards, editors. Elsevier, 2018; Chapter 64: pages 1266-1267.
  78. Morabito KM, Graham BS. Zika Virus Vaccine Development. Journal of Infectious Diseases 2017 Dec 16; 216(suppl_10):S957-S963. doi: 10.1093/infdis/jix464.
  79. Graham BS, Sullivan NJ. Emerging viral diseases from a vaccinology perspective: Preparing for the next pandemic. Nature Immunology 2018 Jan;19(1):20-28. doi: 10.1038/s41590-017-0007-9. Epub 2017 Dec 14.
  80. Voronin Y, Jani I, Graham BS, Cunningham CK, Mofenson LM, Musoke PM, Permar SR, Scarlatti G. Recent progress in immune-based interventions to prevent HIV-1 transmission to children. Journal of the International AIDS Society 2017 Dec;20(4). doi: 10.1002/jia2.25038.
  81. Vekemans J, Moorthy V, Giersing B, Friede M, Hombach J, Arora N, Modjarrad K, Smith PG, Karron R, Graham B, Kaslow D. Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics. Vaccine. 2018 Jan 25. pii: S0264-410X(17)31364-6. doi: 10.1016/j.vaccine.2017.09.092.
  82. Graham BS, Mascola JR, Fauci AS. Vaccine Platform technologies. Journal of the American Medical Association 2018 Apr 10; 319(14):1431-1432. doi: 10.1001/jama.2018.0345.
  83. Erbelding E, Post D, Stemmy EJ, Roberts PC, Augustine AD, Ferguson S, Paules CI, Graham BS, Fauci AS. A Universal influenza vaccine: The strategic plan for the National Institute of Allergy and Infectious Diseases. Journal of Infectious Diseases 2018 Feb 28; doi.org/10.1093/infdis/jiy103.
  84. Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, McLellan JS, Englund JA, Mejias A, Karron RA, Simões EA, Knezevic I, Ramilo O, Piedra PA, Chu HY, Falsey AR, Nair H, Kragten-Tabatabaie L, Greenough A, Baraldi E, Papadopoulos NG, Vekemans J, Polack FP, Powell M, Satav A, Walsh EE, Stein RT, Graham BS, Bont LJ; Respiratory Syncytial Virus Network (ReSViNET) Foundation. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infectious Diseases 2018; Jun 15. pii: S1473-3099(18)30292-5. doi: 10.1016/S1473-3099(18)30292-5.
  85. Ruckwardt TJ, Collins PL, Graham BS. Human Respiratory Syncytial Virus, in Medical Microbiology section of Reference Module in Biomedical Sciences (RMBS), Elsevier, 2018 (http://www.sciencedirect.com/science/referenceworks/9780128012383).
  86. Crank MC, Mascola JR, Graham BS. Preparing for the next influenza pandemic: The development of a universal influenza vaccine. Journal of Infectious Diseases 2019 Jan 31; doi: 10.1093/infdis/jiz043.
  87. Graham BS, Gilman MSA, McLellan JS. Structure-based vaccine antigen design. Annual Review of Medicine 2019 Jan 27; 70:91-104. doi: 10.1146/annurev-med-121217-094234.
  88. Graham BS. Immunological goals for respiratory syncytial virus vaccine development. Current Opinion in Immunology 2019; Apr 24; 59:57-64. doi: 10.1016/j.coi.2019.03.005.
  89. Ruckwardt TJ, Morabito KM, Graham BS. Immunological lessons from respiratory syncytial virus vaccine development. Immunity 2019 Sep 17; 51(3):429-442. doi: 10.1016/j.immuni.2019.08.007.
  90. Ruckwardt TJ, Crank MC, Morabito KM, Graham BS. Vaccination Against Respiratory Syncytial Virus. Mucosal Vaccines: Innovation for Preventing Infectious Diseases, Second edition. Kiyono H, Pascual D, editors. Elsevier, Cambridge, MA, 2020, Chapter 38: pages 665-676.
  91. Wei CJ, Crank MC, Shiver J, Graham BS, Mascola JR, Nabel GJ. Next-generation influenza vaccines: opportunities and challenges. Nature Reviews Drug Discovery 2020 Feb 14; doi: 10.1038/s41573-019-0056-x.
  92. Kanekiyo M, Graham BS. Next-Generation Influenza Vaccines. Cold Spring Harbor Perspectives in Medicine 2020; a038448. doi:10.1101/cshperspect.a038448.
  93. Graham BS, Corbett KS. Prototype pathogen approach for pandemic preparedness: World on fire. Journal of Clinical Investigation 2020 Apr 30:139601. doi: 10.1172/JCI139601.
  94. Graham BS. Rapid COVID-19 vaccine development. Science 2020 May 8; eabb8923. doi: 10.1126/science.abb8923.
  95. Lambert PH, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, Dekker CL, Didierlaurent AM, Graham BS, Martin SD, Molrine DC, Perlman S, Picard-Fraser PA, Pollard AJ, Qin C, Subbarao K, Cramer JP. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine 2020 May 25; S0264-410X(20)30709-X. doi: 10.1016/j.vaccine.2020.05.064.
  96. Muñoz-Fontela C, Dowling WE, Funnell SGP, Gsell PS, Balta XR, Albrecht RA, Andersen H, Baric RS, Carroll MW, Cavaleri M, Qin C, Crozier I, Dallmeier K, de Waal L, de Wit E, Delang L, Dohm E, Duprex WP, Falzarano D, Finch CL, Frieman MB, Graham BS, Gralinski L, Guilfoyle K, Haagmans BL, Hamilton GA, Hartman AL, Herfst S, Kaptein SJF, Klimstra W, Knezevic I, Krause PR, Kuhn JH, Le Grand R, Lewis M, Liu WC, Maisonnasse P, McElroy AK, Munster V, Oreshkova N, Rasmussen AL, Rocha-Pereira J, Rockx B, Rodríguez E, Rogers T, Salguero FJ, Schotsaert M, Stittelaar K, Jan Thibaut H, Tseng CT, Vergara-Alert J, Beer M, Brasel T, Chan JFW, García-Sastre A, Neyts J, Perlman S, Reed DS, Richt JA, Roy CJ, Segalés J, Vasan SS, Henao-Restrepo AM, Barouch DH. Animal models for COVID-19. Nature 2020 Sep 23; doi: 10.1038/s41586-020-2787-6.
  97. DiPiazza AT, Graham BS, Ruckwardt TJ. T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochemical Biophysical Research Communications 2020 Oct 23; S0006-291X(20)31983-5. doi: 10.1016/j.bbrc.2020.10.060.
  98. Connors M, Graham BS, Lane HC, Fauci AS. SARS-CoV-2 Vaccines: Much accomplished, much to learn. Annals of Internal Medicine 2021 Jan 19; doi: 10.7326/M21-0111.
  99. Mascola JR, Graham BS, Fauci AS. SARS-CoV-2 viral variants: Tackling a moving target. JAMA. 2021 Feb 11; doi: 10.1001/jama.2021.2088.
  100. Bok K, Sitar S, Graham BS, Mascola JR. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity 2021 Aug 3; S1074-7613(21)00303-4. doi: 10.1016/j.immuni.2021.07.017.
  101. Morabito KM, Milutinovic P, Graham BS, Pierson TC. Zika Virus Vaccines in “Plotkin’s Vaccines”, Eighth edition, Walter A. Orenstein, Paul A. Offit, Kathryn M. Edwards, with Stanley A. Plotkin, editors. Elsevier, 2022; Chapter 65: pages .
  102. Sparrow E, Adetifa I, Chaiyakunapruk N, Cherian T, Fell DB, Graham BS, Innis B, Kaslow DC, Karron RA, Nair H, Neuzil KM, Saha S, Smith PG, Srikantiah P, Were F, Zar HJ, Feikin D. WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use. Vaccine 2022 Feb 17; S0264-410X(22)00186-4. doi: 10.1016/j.vaccine.2022.02.040.

Editor for Books and Special Compiled Journal Editions

  1. Larry J. Anderson and Barney S. Graham, editors for Challenges and Opportunities for Respiratory Syncytial Virus Vaccines, in the series, “Current Topics in Microbiology and Immunology”, Springer, Heidelberg, Germany. 2014, pages 404. (66,955 downloads as of August 2018, 2-3 times more than average for discipline).
  2. Michelle C. Crank and Barney S. Graham, editors for Universal Influenza Vaccine Progress in the 100 Years Since 1918 published as a special supplementary edition for Journal of Infectious Diseases, Oxford University Press, NY, NY. 2019, pages 109.

 Published Letters and Book Reviews

  1. Graham B, Theil GB, Gregory DW. Smoking, hot and cold drinks, pulse and temperature (letter). Annals of Internal Medicine 1983; 98:559-560.
  2. Nolop KB, Graham BS, Bernard G. High-level PEEP in severe asthma (letter). New England Journal of Medicine 1983; 308:725-726.
  3. Graham BS, Ukwu H, Latham RH. Acute pubic osteomyelitis - Reply. Clinical Infectious Diseases 1993; 16:828.
  4. Weinhold KJ, Tartaglia J, Paoletti E, Graham B, Schwartz D, McElrath J, Roberts N, Gorse G. Specific activation strategies for amplification of low CTL signals. AIDS Research and Human Retroviruses. 1992; 8(8):1373.
  5. Neuzil KM, Gruber WC, Chytil F, Stahlman MT, Graham BS. Vitamin A for varicella - Reply. Journal of Pediatrics 1994; 124:1017-1018.
  6. Neuzil KM, Gruber WC, Graham BS. Vitamin A therapy for respiratory syncytial virus infection (letter). The Pediatric Infectious Disease Journal 1997; 16:84-85.
  7. Graham BS. Nonexertional heatstroke (letter). Annals of Internal Medicine 1999; 130:613-614.
  8. Graham BS, Johnson TR, Peebles RS, Fischer JE. Filamentous hemagglutinin and pertussis toxin from Bordetella pertussis modulate immune responses to unrelated antigens - Reply. Journal of Infectious Diseases 2000; 182:1288-1289.
  9. Bredenberg HK, Graham BS. Hospitalization costs of respiratory syncytial virus infection. The Pediatric Infectious Disease Journal 2001; 20:1100-1101.
  10. Review and comments on back cover of DuBois L. More Than a Place: The Founding of Vanderbilt Children’s Hospital. Providence House Publishing. Franklin, TN. 2007.
  11. Martin JE, Pierson TC, Graham BS. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. Reply to Rottinghaus and Poland. Journal of Infectious Diseases 2008; 197:1628-1629.
  12. Ledgerwood JE, Sullivan NJ, Graham BS. Chimpanzee adenovirus vector Ebola vaccine--Preliminary report – Reply to Zhang and Seto. New England Journal of Medicine. 2015 Aug 20; 373(8):776. doi: 10.1056/NEJMc1505499.
  13. Jackson LA, Roberts PC, Graham BS. A SARS-CoV-2 mRNA vaccine - Preliminary report. Reply. New England Journal of Medicine 2020 Aug 19; 383(12):10.1056/NEJMc2026616#sa3. doi: 10.1056/NEJMc2026616.